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Mary L. Cox 
THE ROLE OF THE CTD PHOSPHATASE RTR1 AND POST-TRANSLATIONAL 
MODIFICATIONS IN REGULATION OF RNA POLYMERASE II  
RNA polymerase II (RNAPII) is regulated by multiple modifications to the C-
terminal domain (CTD) of the largest subunit, Rpb1. This study has focused on the 
relationship between hyperphosphorylation of the CTD and RNAPII turnover and 
proteolytic degradation as well as post-translational modifications of the globular core of 
RNAPII. 
Following tandem affinity purification, western blot analysis showed that MG132 
treated RTR1 ERG6 deletion yeast cells have accumulation of total RNAPII and in 
particular, the hyperphosphorylated form of the protein complex. In addition, proteomic 
studies using MuDPIT have revealed increased interaction between proteins of the 
ubiquitin-proteasome degradation system in the mutant MG132 treated yeast cells as well 
as potential ubiquitin and phosphorylation sites in RNAPII subunits, Rpb6 and Rpb1, 
respectively. A novel Rpb1 phosphorylation site, T1471-P, is located in the linker region 
between the CTD and globular domain of Rpb1 and will be the focus of future studies to 
determine biological significance of this post-translational modification.  
 
     Mark G. Goebl, PhD. Chair 
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INTRODUCTION 
I. The regulation of RNA Polymerase II transcription elongation 
Transcription of DNA into cellular RNAs is accomplished by one of three highly 
conserved enzymes in higher eukaryotes (Vannini & Cramer, 2012). In eukaryotes, RNA 
polymerase II (RNAPII) is primarily responsible for transcribing DNA into messenger 
RNA (mRNA) as well as small nuclear RNA (snRNA) (Corden, Cadena, Ahearn, & 
Dahmus, 1985; D. W. Zhang et al., 2012). When completely assembled, the RNAPII 
holoenzyme (Figure 1), is ~550KDa consisting of 12 subunits, designated Rpb1 through 
Rpb12 (Edwards, Kane, Young, & Kornberg, 1991; Woychik & Young, 1990).  A unique 
feature of the largest subunit, Rpb1, is a hepta-peptide repeat (Y1S2P3T4S5P6S7 ) hence 
referred to as the C-terminal domain (CTD)that is important for determining whether the 
RNAPII  will initiate transcription based on the phosphorylation status of the hepta-
peptide repeats (Cadena & Dahmus, 1987; Payne, Laybourn, & Dahmus, 1989; Phatnani 
& Greenleaf, 2006).  
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The transcription cycle is a well-coordinated series of processes which must begin 
with an initiation competent RNAPII complex associating with the promoter region of 
the DNA template strand. The CTD has been shown to be a functional scaffold that 
coordinates transitions between transcription initiation, promoter clearance, elongation, 
and termination through dynamic changes in post-translational modifications along the 
CTD repeats (described in detail  below and reviewed in Heidemann, Hintermair, Voss, 
& Eick, 2013). In addition, modifications of interacting protein factors aid in the 
regulation of the transcription cycle through signals that act to promote or repress 
Clamp 
Likely CTD exit 
Figure 1. PDB-Viewer/Pov Ray generated model of complete ribbon structure for RNAPII 
complex. The crystal structure was determined by Armache et al. in 2005 (PDB ID: 1WCM).  
This model indicates structural features that are critical for major transcription functions.  
3 
 
transcription (Bataille et al., 2012; Phatnani & Greenleaf, 2006; Shandilya & Roberts, 
2012). 
Initiation of transcription begins following hypophosphorylated RNAPII binding 
to a promoter of a gene (Laybourn & Dahmus, 1989; Lu, Flores, Weinmann, & 
Reinberg, 1991; Ohkuma & Roeder, 1994). Recruitment of this form of RNAPII is 
achieved through recognition of the pre-initiation complex (PIC) which includes general 
transcription factors (GTFs) such as TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH. 
These GTFs facilitate a stable transcription competent complex at the promoter through 
a number of biochemical activities including: suppression of promoter-proximal stalling 
of RNAPII, promoter DNA melting, RNA Polymerase II loading onto the template 
strand, and stimulation of productive transcription (Cramer, 2004; Hirose & Ohkuma, 
2007; Hsin & Manley, 2012).   Specifically, immediately following RNAPII binding to 
the promoter, the CTD is phosphorylated at the S5 residue by a TFIIH-associated cyclin-
dependent kinase, Kin28 (Komarnitsky, Cho, & Buratowski, 2000) and occupancy of the 
S5 phosphorylated modified occupancy peaks shortly thereafter in a 5’ transition of 
initiation to elongation (Mayer et al., 2010). Within the last few years, genome-wide 
analysis of general elongation factors in yeast transcription have been well characterized 
using chromatin immunoprecipitation (ChIP) followed by microarray, which  has shown 
that elongation factors are often recruited during a short transition just upstream of the 
transcription start site (TSS) (Mayer et al., 2010). While the initiation and termination 
factors were found to peak just before and just after the TSS and the polyadenylation 
sites (pA), respectively, several elongation factors (e.g. Spt4, Spt5, Spt6, Spt16, Spn1, 
Elf1, Bur1 and Ctk1) were found to have increased gene-averaged occupancy intensities 
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from ChIP and microarray studies. These intensities did not correlate to either initiation 
or termination factors and showed three distinct patterns of association based on when 
they are active in the transcription cycle (Mayer et al., 2010). These results support a 
coordinated exchange of the initiation complex for an elongation complex at the 5’ end 
of the transcribed region in a uniform transition (Mayer et al., 2010).   
The 5’ transition from initiation to elongation is marked by the release of RNAPII 
from the promoter with enhanced levels of serine 5 phosphorylation (S5-P) persisting 
throughout early and mid-elongation. Meanwhile, simultaneous recruitment of capping 
and splicing proteins (Fabrega, Shen, Shuman, & Lima, 2003; Mayer et al., 2010; 
Schroeder, Schwer, Shuman, & Bentley, 2000) occurs which begin to process the 
lengthening mRNA at the 5’ end.  As the RNAPII moves along the transcribed region of 
the gene, the shift of the CTD phosphorylated at serine 5 to serine 2 (S2-P) occurs 
through the activity of a cyclin-CDK kinase complex known as CTDK-1 (containing the 
cyclin dependent kinase subunit Ctk1).  Consequently, at the 3’ end of the transcribed 
region the CTD is populated predominantly with S2-P CTD at transcription termination 
of many RNAPII target mRNA genes. As with the 5’ end, termination of transcription is 
marked by dissociation of many of the elongation factors and RNAPII in a coordinated 
manner to facilitate the completion of the transcription cycle. During the first step of this 
two-step process, several elongation factors are released (Spt16, Paf1, Bur1 and Ctk1) 
and the second step of transcription termination involves association of processing and 
termination factors with RNAPII that facilitate the cleavage and subsequent 
polyadenylation by the CPF (cleavage and polyadenylation factors) (Licatalosi et al., 
2002; Mayer et al., 2010; Y. Zhang, Wen, Washburn, & Florens, 2011). Finally, prior to 
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re-initiation of transcription by hypophosphorylated RNAPII, S5-P and S2-P residues of 
the CTD are dephosphorylated by specific phosphatase activity described in more detail 
in the following sections.    
II. Post-translational modification of RNA Polymerase II 
Post-translational modifications (PTM) are key biochemical signals that 
determine regulation of transcription and many other cellular processes. The 26 
consecutive repeats of the heptamer Y1S2P3T4S5P6S7 in the yeast CTD (Allison, Moyle, 
Shales, & Ingles, 1985) has multiple potential sites for post-translational modification 
such as phosphorylation, glycosylation, and methylation (reviewed in Ponts et al., 2011).  
Phosphorylation of the CTD is the most widely studied and best characterized among 
these modifications, as discussed in the previous section, with the majority of previous 
studies centered on the serine residues at positions 2, 5, and  to a lesser extent 7 ( S7-P) 
(Chapman et al., 2007; Egloff, Zaborowska, Laitem, Kiss, & Murphy, 2012). Although 
these phosphorylation sites are the most widely studied, there is an increasing number of 
studies exploring phosphorylated tyrosine in the first position (Heidemann & Eick, 
2012) and phosphorylated threonine in the fourth position (Heidemann et al., 2013; 
Sardiu & Washburn, 2011b). In addition, isomerization of the proline residues in 
positions 3 and 5 have been found to add to the complexity of the “CTD code” 
(reviewed in Buratowski, 2003; Egloff, Dienstbier, & Murphy, 2012).  
It is known that RNAPII must be in a hypophosphorylated state in order to 
become initiation competent in vitro  (Laybourn & Dahmus, 1989), though the 
dephosphorylation events that create this RNAPII form are incompletely understood and 
questions still remain (Egloff, Dienstbier, et al., 2012). The following is a brief summary 
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of the relevant modifications beginning with RNAPII binding to a DNA promoter. As 
discussed above, the kinase Kin28 (yeast homolog to CDK7 in higher eukaryotes), a 
member of the TFIIH initiation complex, phosphorylates the CTD at S5 residues 
(Komarnitsky et al., 2000; Rodriguez et al., 2000). As the complex clears the promoter 
of an actively transcribing gene, S5-P peaks near the 5’ end of the transcribed region, 
which also triggers the recruitment of capping and splicing components (Schroeder et 
al., 2000) to the transcript. S5-P decreases significantly due to the phosphatase activity 
of Rtr1 (Egloff, Zaborowska, et al., 2012; M. Kim, Suh, Cho, & Buratowski, 2009; 
Mosley et al., 2009) and Ssu72 (Komarnitsky et al., 2000) during the course of 
elongation. Dephosphorylation of S5-P coincides with protein kinases Ctk1 (human 
homolog is CDK9 part of the P-TEFb) and/or Bur1 (human homolog CDK9 and 
CDK12) phosphorylation of S2 residues on the CTD   (K. K. Lee et al., 2011; Qiu, Hu, 
& Hinnebusch, 2009). S7 phosphorylation also steadily occurs as RNAPII moves along 
the transcribed region during transcription elongation by the activity of Kin28 (Akhtar et 
al., 2009; Glover-Cutter et al., 2009; M. Kim et al., 2009).The phosphorylation of the S7 
residue has been implicated in snRNA transcription and processing (Chapman et al., 
2007; Egloff, Zaborowska, et al., 2012; Sardiu & Washburn, 2011a). It has also been 
hypothesized that S7-P could be used as a mechanism of suppression of cryptic 
transcription resulting from interrupted transcription and enhanced transcription (Tietjen 
et al., 2010). In addition, Bataille and colleagues recently (Bataille et al., 2012; D. W. 
Zhang et al., 2012) attributed dephosphorylation of S7-P to Ssu72 using both in vivo and 
in vitro studies.  
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S2-P peaks at the 3’ end of the transcribed region and signals recruitment of 
termination factors necessary for the cleavage and polyadenylation of the nascent RNA 
(Ahn, Kim, & Buratowski, 2004; L. Chen et al., 2011; Licatalosi et al., 2002; Ramisetty 
& Washburn, 2011). At or immediately following termination of transcription the S2-P 
are removed by the protein phosphatase, Fcp1. In addition to the above modifications, 
the propyl isomerase, Ess1 (Pin1 in humans), which catalyzes the conversion of cis/trans 
petidyl proline bond at S5-P6 of the CTD repeat,  has been linked to stimulation of 
Ssu72 dephosphorylation of S5-P and S7-P at the 3’ end of genes (Bataille et al., 2012). 
This modification is important due to the recent finding that the cis-isomer was the 
preferred substrate for Ssu72 binding and CTD phosphatase activity (Werner-Allen et 
al., 2011; Xiang et al., 2010).  
Phosphorylation patterns of the actively transcribing RNAPII CTD have been 
shown to be essential to the successful transcription and processing of mRNA (recently 
reviewed in Egloff, Dienstbier, et al., 2012; Ponts et al., 2011). As a consequence, the 
loss of phosphatase activity has been implicated in the loss of RNAPII occupancy and 
the inability to form competent initiation complexes in vitro (Cho et al., 1999; Laybourn 
& Dahmus, 1989; Mosley et al., 2009). The resulting hyperphosphorylation of the CTD 
due to inefficient or non-existent dephosphorylation could account for the lack of 
initiation competent RNAPII and lower gene occupancy in the transcribed region. In 
order to test this hypothesis, the use of phosphatase deletion or thermosenstive strains of 
S. cerevisiae is proposed to explore whether RNAPII recycling or degradation is 
affected by the loss of CTD phosphatases and subsequent hyperphosphorylation. In 
addition, the use of MuDPIT analysis will be used to identify potential post-translational 
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modifications that occur following deletion of the CTD phosphatase, RTR1. Finally, 
MuDPIT analysis will also be used to determine if additional interactions with specific 
factors can be identified that may add insight to potential mechanisms for RNA 
recycling.  
III. Overview of current known role of Rtr1 and other CTD Phosphatases  
Figure 2 shows our current working model of the role of RNAPII CTD 
phosphorylation with an emphasis on phosphatase activity. The specific roles of these 
phosphatases will be investigated further in this present study. In order to test this model 
it is important to first understand the existing protein kinase and phosphatase activities.  
 
Figure 2. Model of regulation of phosphorylation of the RNA Polymerase II CTD during transcription 
elongation in S. cerevisiae.  The roles of the three known protein phosphatases are hypothesized as 
indicated by serine phosphorylation patterns on the CTD. Dephosphorylation of S5 occurs in early 
elongation through the activity of Rtr1 (Mosley, et al. 2009), whereas Ssu72 activity has been 
implicated in removal of S5 from the CTD at the 3’ end of the gene and is associated with the cleavage 
and polyadenylation of the nascent transcripts (Krishnamurthy et al., 2004). Fcp1 catalyzes the removal 
of phosphates from S2 residues and has been implicated in recycling of RNAPII to a stable initiation 
complex at the promoter (Cho, Kober et al., 2001).    
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As presented in Table 1, the paired activity of the protein kinases and 
phosphorylation occur throughout the transcription cycle. It should be mentioned that the 
human homologs of the yeast phosphatases have been identified and found to associate 
with RNAPII (Table 1) (Clemente-Blanco et al., 2011; Egloff, Dienstbier, et al., 2012; 
Sardiu & Washburn, 2010; D. W. Zhang et al., 2012). Given the importance of the 
activity of dephosphorylation of the RNAPII, it is expected that defects of these 
regulatory genes have dire consequences. One prominent example is the human homolog 
of FCP1 (CTDP1) which has been unequivocally linked to a human disease. Congenital 
cataracts facial dysmorphism neuropathy (CCFDN) is an autosomal recessive, single 
 
nucleotide change in intron 6 of the CTDP1 gene which encodes the transcription 
phosphatase, FCP1 (Varon et al., 2003). This single nucleotide change causes 
destabilization of the FCP1 mRNA causing a 30% down-regulation in mRNA levels. The 
characteristics of the disease are abnormalities of the eye including bilateral cataracts, 
Table 1. Summary of CTD kinases and phosphatases in S. cerevisiae and 
mammals 
CTD 
Residue 
Function Mammals S. cerevisiae Active Transcription Phase 
S2 
Kinase 
Cdk9, Cdk12 
(Cdk13?) 
Bur1, Ctk1 Elongation 
Phosphatase Fcp1, Cdc14 Fcp1 Late Elongation/Termination 
S5 
Kinase 
Cdk7, Cdk8 Kin28, Cdk8 
(Srb10) 
Early Elongation 
Phosphatase 
RPAP2, Scp1, 
Ssu72?, Cdc14 
Rtr1, Ssu72 Early Elongation (yeast Rtr1)/Late 
Elongation/Termination (yeast 
Ssu72) 
S7 
Kinase Cdk7, Cdk9 Kin28, Bur1 Early Elongation 
Phosphatase Ssu72? Ssu72 Late Elongation/Termination 
T4 Kinase Cdk9? ? ? 
? Enzyme has not been identified or suggested enzyme has not been confirmed as having this 
function. Table adapted from (Egloff et al., 2012) 
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microcornea and microphthalmia; dysmorphic facial features, and distal peripheral 
neuropathy (Kalaydjieva, 2006).    
As detailed in our current working model (Figure 2), each CTD phosphatase is 
responsible for the removal of a specific phosphorylation event on the CTD during the 
transcription cycle, although some overlap exists (i.e. Rtr1 and Ssu72 removal of S5-P). 
It is not known whether each phosphatase recognizes the modification, catalyzed by a 
particular kinase or is specific to a particular set of CTD modifications with the 
exception of Ssu72 recognition of proline isomerization catalyzed by Ess1 (Werner-
Allen et al., 2011) or doubly modified heptad repeats (i.e. CTD with S2-P and S5-P).  In 
this thesis we will study the RNAPII modifications on both the CTD and the globular 
core of the enzyme in the presence and absence of Rtr1.   
IV. Mechanisms for RNAPII degradation and recycling pathways 
RNAPII recycling is necessary to enable continuous transcription cycles in 
actively growing eukaryotic cells. Actively transcribing RNAPII must overcome many 
obstacles that impede elongation and ultimate completion of mRNA production. 
Obstacles such as nucleosomal blocks, sites of DNA damage, and specific sequences 
result in natural pausing of the RNAPII independent of the regulatory factors associated 
with transcription (Svejstrup, 2007; Wilson, Harreman, & Svejstrup, 2013). Many of the 
key regulatory factors that enhance transcription activity are regulated by the 
phosphorylation state of the RNAPII CTD. The creation of initiation competent RNAPII 
following a completed transcription cycle is ultimately dependent upon the activities of 
the three characterized CTD phosphatases since hyperphosphorylation of the CTD of 
Rpb1 has been shown to reduce RNAPII occupancy on active genes in the event of CTD 
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phosphatase defects (Gilmore & Washburn, 2010; Laybourn & Dahmus, 1989; Mosley et 
al., 2009; Reyes-Reyes & Hampsey, 2007). One specific mechanism that has been 
hypothesized for efficient recycling of competent RNAPII complexes is gene looping 
(Sardiu et al., 2009; Singh & Hampsey, 2007). The phenomenon involves the physical 
interaction between the promoter and termination regions of a transcribed gene.  
Evidence has been found that links the promoter bound re-initiation scaffold through the 
GTF TFIIB which is known to associate with the CPF (El Kaderi, Medler, 
Raghunayakula, & Ansari, 2009). Of particular interest is the finding that Ssu72 was 
involved in the process (Singh & Hampsey, 2007; Tan-Wong et al., 2012) due to genetic 
and physical links to TFIIB. A second CTD phosphatase, Fcp1, has also been shown to 
play a significant role in RNAPII turnover following transcription termination (Fuda et 
al., 2012; Kobor et al., 1999). As a S2-P phosphatase, Fcp1 activity is essential in the 
creation of hypophosphorylated RNAPII which can then reinitiate transcription (Gilmore 
& Washburn, 2010; Kobor et al., 1999). Normal recycling of RNAPII through gene 
looping is advantageous to transcription in that it allows efficient use of pre-assembled 
complexes in response to dynamic environmental signals; however, when blocks to 
transcription are encountered or defects exist in any of the regulatory accessory proteins 
or complexes (i.e. Mediator, PIC, CPF, or capping, splicing, and/or 3’ end processing 
machinery), transcription may be irrevocably arrested until extraordinary means of rescue 
are employed.  
Natural stalling of transcribing RNAPII complexes occurs frequently in the 
dynamic process of gene expression (Svejstrup, 2002; Wilson et al., 2013). Causes of this 
stalling can be dense chromatin structures, nucleosomal blocks, GC rich areas on the 
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coding DNA strand and DNA damage caused by UV irradiation. One mechanism 
described for rescue of stalled RNAPII sites of DNA damage or dense chromatin 
structure utilizes ubiquination to target stalled RNAPII (Anindya, Aygun, & Svejstrup, 
2007; Reid & Svejstrup, 2004; Somesh et al., 2005; Svejstrup, 2007; Woudstra et al., 
2002; Y. Zhang, Wen, Washburn, & Florens, 2009). This type of recycling or 
Transcription Coupled Repair (TCR) associated with DNA damage is accomplished 
through the mechanisms of Nucleotide Excision Repair (NER) or Base Excision Repair 
(BER). In both cases, the repair proteins rapidly converge and interact with the stably 
associated RNAPII/DNA/RNA ternary complex (Somesh et al., 2005; Svejstrup, 2002) 
when a DNA lesion is encountered during transcription elongation. When recruitment of 
repair factors is unsuccessful in rescuing the stalled RNAPII elongation complex, the 
RNAPII is marked for degradation by the ubiquitin/proteasome degradation pathway 
through addition of polyubiquitin chains (Somesh et al., 2007; Y. Zhang et al., 2009). In 
fact, two ubiquitin sites have been identified on the largest RNAPII subunit, Rpb1 at 
positions K330 and K695 by Somesh et al. (2005, 2007). Also of note is studies 
conducted by the same group, in which a correlation was found between increased 
turnover of Rpb1 with ubiquitin modification under DNA damaging conditions (Somesh 
et al., 2005). Although Rbp1 has been a focus of current studies, there is little known 
about the effects of TCR-coupled ubiquitination and subsequent proteasomal degradation 
on other RNAPII subunits. Multiple studies have suggested that the cytotoxic effect of 
proteasome inhibitors on tumor cells is related to suppression of DNA repair pathways 
(reviewed in Motegi, Murakawa, & Takeda, 2009; Vlachostergios, Patrikidou, Daliani, & 
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Papandreou, 2009). It is therefore important to understand the mechanisms by which the 
ubiquitin modification and proteasome degradation of RNAPII are involved in TCR.  
V. Proteasome inhibition and alternative approaches to study protein turnover 
The proteasomal degradation pathway is an essential mechanism for cellular 
processes, such as quality control, cell cycle, transcription, protein transport, and DNA 
repair. When combined, the 19S regulatory subunit and the 20S proteolytic core subunit 
of the proteasome (Swanson, Florens, & Washburn, 2009) is designated 26S proteasome. 
Located at the ends of the cylindrical 20S proteolytic core (or CP), the 19S (or RP) is 
responsible for the recognition and removal of ubiquitin chains from target proteins in an 
ATP-dependent reaction as it directs that target protein through the narrow channel 
leading to the center of the protease active site for subsequent degradation of the target 
protein. As discussed above, RNAPII pauses occur frequently during transcription and 
these arrests must be resolved in a timely and efficient manner in order to avoid ubiquitin 
tagging and proteasomal degradation. Figure 3 depicts a model of a stalled RNA and the 
potential ubiquitin labeling in preparation of proteasomal recognition and degradation.  
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Preliminary data collected by Amber Mosley indicate that the loss of the CTD 
phosphatase, Rtr1, leads to decreased RNAPII occupancy on active genes (Mosley et al., 
2009) as well as an increased association between polymerase and the proteasome as 
determined by proteomic analysis using mass spectrometry (Table 2). This data, along 
with previously discussed studies involving hyperphosphorylation in deletion strains with 
the inability to form initiation competent RNAPII, leads to a modification in our working 
model (Figure 4) and our hypothesis that the loss of RNAPII recycling is observed in vivo 
in CTD phosphatase mutant strains for rtr1Δ, fcp1Δ, and ssu72Δ. With a loss of the 
ability to reinitiate transcription and the potential for increased RNAPII stalling, it is 
possible that hyperphosphorylated RNAPII complexes are marked for degradation and 
removal from transcription sites. This hypothesis makes an assumption that the 
dephosphorylation targets in RNAPII for Rtr1, Ssu72, and Fcp1 are different and 
Figure 3. RNAPII naturally pauses during transcription elongation. Fully stalled or arrested RNAPII 
results in a barrier to mRNA production that the cell must deal with quickly and efficiently. If the 
stalled RNAPII cannot overcome the obstacle to transcription, the polymerase is targeted for 
ubiquitination and degraded by the 26S proteasome.  
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therefore loss of any one phosphatase cannot be compensated for.  This question is of 
broad interest and is being addressed by a number of different experiments carried out by 
other members of the laboratory. 
Table 2. Selection of proteins identified by MudPIT analysis of Rpb3-TAP strains 
  Rpb3-TAP Purification from 
Wild-type cells 
Rpb3-TAP Purification from rtr1∆ 
cells 
Protein 
Acronym 
Total 
Number 
of 
Peptides 
Detected 
NSAF 
Sequence 
Coverage 
Total 
Number 
of 
Peptides 
Detected 
NSAF 
Sequence 
Coverage 
Rpb1 3906 0.085831 64.50% 3264 0.059932 63.30% 
Rpb2 4025 0.125225 75.10% 3583 0.93148 63.70% 
Rpb3 970 0.116159 76.20% 1245 0.124581 71.70% 
Rpb4 495 0.085294 81.00% 667 0.096038 71.50% 
Rpb5 276 0.048885 55.30% 505 0.074742 48.80% 
Rpb6 57 0.014004 58.10% 146 0.029973 45.80% 
Rpb7 249 0.055451 87.10% 313 0.58245 84.80% 
Rpb8 346 0.090247 50.70% 209 0.045552 50.70% 
Rpb9 111 0.034647 66.40% 136 0.035472 66.40% 
Rpb10 323 0.175717 54.30% 465 0.211381 62.90% 
Rpb11 280 0.88856 59.20% 250 0.066293 62.50% 
Rpb12 58 3031553 60.00% 74 0.033639 60% 
Spt5 18 0.000645 14.70% 32 0.000958 17% 
Ubiquitin 0 0 0 5 0.002093 32.90% 
Pre10 0 0 0 2 0.000221 4.90% 
Pre6 0 0 0 1 0.000125 5.50% 
Pup2 0 0 0 1 0.000122 5.40% 
Rpn1 0 0 0 6 0.000192 5% 
Rpn2 0 0 0 1 0.000034 1.20% 
Rpt1 0 0 0 9 0.000613 10.90% 
Rpt2 0 0 0 1 0.000073 4.80% 
Rpt4 0 0 0 6 0.000147 10.50% 
Rpt5 0 0 0 5 0.000367 8.50% 
Rpt6 0 0 0 2 0.000157 6.40% 
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  The approach we will use to examine the proteasome dependent degradation of 
RNAPII through chemical induction of proteasomal inhibition. There are several peptide 
aldehyde inhibitors of proteasomes that have been used reliably in yeast mutated to 
enhance permeability (D. H. Lee & Goldberg, 1996). These inhibitors function by 
blocking the active sites of the proteasome (Gaczynska & Osmulski, 2005). One specific 
reagent that has been used in relevant experiments is Carbobenzoxyl-leucinyl-lucinyl-
leucinal (MG132) (X. Chen, Ruggiero, & Li, 2007; D. H. Lee & Goldberg, 1996; Liu, 
Apodaca, Davis, & Rao, 2007; Rock et al., 1994). To test our model, we will inhibit 
proteasome function to determine if hyperphosphorylated RNAPII accumulates further 
with disruption of Rtr1 function and proteasome inhibition.  
Normally, wild type (WT) yeast cells are impermeable to MG132; however, this 
can be overcome using an erg6Δ deletion in our strain of study (D. H. Lee & Goldberg, 
Figure 4. Current working model for RNAPII recycling and degradation following the loss of CTD 
phosphatases. We hypothesize that hyperphosphorylated RNAPII will be unable to initiate 
subsequent transcription cycles and are therefore ubiquitinated and targeted for degradation by the 
proteasome.  
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1996). ERG6 is a methyltransferase enzyme involved in biosynthesis of ergosterol and 
normal cell membrane function and defects create leakage of the membrane (Gaber, 
Copple, Kennedy, Vidal, & Bard, 1989; Jensen-Pergakes et al., 1998). The use of mutant 
yeast strains with enhanced permeability as background to CTD phosphatase deletions 
will allow the cells to take up the drug resulting in the inhibition of proteasome function. 
In addition, each strain will be modified with the addition of a TAP tag to the C-terminus 
of Rpb3 polymerase subunit at its endogenous locus (Washburn, 2008). Purification 
using Tandem Affinity Purification (TAP) of both erg6Δ and erg6Δrtr1Δ could reveal 
novel interactions involved in signaling for proteasome degradation.  
  There are several alternatives to using proteasome inhibition to study the role of 
CTD phosphatases in regulation of RNA Polymerase II recycling. For example, the use 
of temperature-sensitive alleles of some of the predominant 26S subunits (ie PRN5 and 
PRN6 from the 19S RP and PUP2, PRE8, and PRE1 from the 20S CP) along with CTD 
phosphatase mutants would allow proteomic studies to be conducted without risking 
lethal deletions. The altered function of these proteins can be investigated using tagged 
constructs to aid in co-purification schemes through TAP. Another approach would use 
strains with a ubiquitin tag incorporated into the genome, similar to the TAP tag. This 
approach has been successful recently by Starita et al. (Starita, Lo, Eng, von Haller, & 
Fields, 2012) in studies which expressed only 8XHis tagged ubiquitin. The His-tagged 
proteins were isolated, purified and subjected to liquid chromatography tandem mass 
spectrometry (LC-MS/MS). Alternative studies could express this tagged-ubiquitin in a 
phosphatase deletion background (ie. rtr1Δ, fcp1Δ, and ssu72Δ) and subject isolated 
proteins to affinity enrichment and LC-MS/MS.  
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VI. Transformation of yeast for C-terminal domain tagging via homologous 
recombination 
Transformation of yeast strains for the purpose of introducing stably expressed 
fusion tags to investigate gene expression in an efficient and cost effective manner is 
quickly becoming a standard method of proteomic scientists (Banks, Kong, & Washburn, 
2012; Li, 2011). The method development began with the discovery that E.coli DNA 
could be stably integrated into a yeast chromosome in an additive or substitutive manner 
(Hinnen, Hicks, & Fink, 1978). Adding to this finding, Orr-Weaver et al., (1981) 
described a new method of integration for circular and linear plasmid DNA into yeast 
chromosomes using the cellular mechanism of double strand break repair. This improved 
the efficiency of integration and defined integration points within the yeast genome (Orr-
Weaver, Szostak, & Rothstein, 1981).  
Methods of improving transformation efficiency were also explored at that time 
and one in particular is still being used today. Gietz et al. determined an optimized 
transformation method that increased efficiency to 1.2 x 106 transformants per ug of 
plasmid DNA (Gietz, St Jean, Woods, & Schiestl, 1992) through the introduction of a 
single-stranded DNA (ssDNA) carrier to bind to the permeable cell membrane allowing 
the transforming DNA to work in the nucleus. Another improvement was developed in 
1993 by Baudin et al. who used the polymerase chain reaction (PCR) amplification of 
transforming DNA fragments which include oligonucleotides synthesized with homology 
to chromosomal targets and a selectable marker (Baudin, Ozier-Kalogeropoulos, 
Denouel, Lacroute, & Cullin, 1993). The high rate of homologous recombination in yeast 
allowed researchers to forgo the need to construct plasmids to introduce exogenous 
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genetic material and instead use PCR to amplify only the region that is needed for 
transformation (Baudin et al., 1993; Puig et al., 1998). This development of gene 
disruption cassettes became an attractive system to incorporate a method for native 
protein purification. Along with their colleagues, Riguat and Puig exploited the features 
of transformation with the use of methods described previously (Puig et al., 2001; Rigaut 
et al., 1999) including a disruption cassette that would allow for tandem affinity 
purification of tagged protein targets at the C-terminus of the endogenous locus with a 
TAP tag. The TAP tag includes a Stapholococcus aureus calmodulin binding protein 
sequence (CBP),  followed by a Tobacco Etch Virus (TEV) protease cleavage site and the 
IgG binding domain of Protein A of S. aureus linked to a selection marker, such as URA3 
(Rigaut et al., 1999; Washburn, 2008).  
As shown in Figure 5, the TAP tag structure includes a two step-affinity sequence 
as well the purification strategy used for tagging native proteins (Puig et al., 2001; Rigaut 
et al., 1999). The tagged protein in this method acts as bait for immunoprecipitation of 
any proteins in direct interaction or indirect interaction through other subunits of larger 
functional protein complexes.   
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Purification of proteins in physiologically non-denaturing conditions is necessary 
to maintain native activity related to function and protein interactions. The studies 
presented here utilized the above TAP method adapted by Mosley et al. (Mosley et al., 
2009) to increase the solubility of DNA and chromatin-associated proteins through the 
addition of heparin sulfate and DNAseI treatment, which was added following extract 
preparation but prior to centrifugation to tag and isolate the RNAPII subunit, Rpb3 
(Mosley et al., 2009). The goal was to identify protein interactions and post-translational 
modifications through multidimensional protein identification technology. A schematic 
of the disruption cassette prepared for this experiment can be found in Figure 6. 
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VII. Multidimensional protein identification technology (MuDPIT) to determine 
protein-protein interaction and potential post-translational modifications 
  Multidimensional protein identification technology (MuDPIT) was developed in 
2001 by Washburn and colleagues and couples two methods commonly employed for 
protein analysis; liquid chromatography and mass spectrometry (Washburn, Wolters, & 
Yates, 2001). These analytical methods individually can provide information about 
specific molecular properties of proteins within a complex, heterogeneous sample; 
however in combination, they have become a first line technology in protein 
identification. The evolution of the current technology occurred more than a decade ago 
when it became clear that there was a real need for more efficient, accurate and 
comprehensive means of identifying proteins interacting in complex biological systems 
Figure 6. Schematic of TAP tag disruption cassette used to create Rpb3-TAP S. cerevisiae strains. 
22 
 
(J. S. Lee et al., 2007; Link et al., 1999; Washburn et al., 2001). Development of the 
method was improved with the addition of pre-separation sample enrichment using TAP 
technology as described in the previous section (Bauer & Kuster, 2003; Florens et al., 
2006; Graumann et al., 2004). Reduction in the complexity of the protein mixture as part 
of the overall experimental study design is often necessary due to the overwhelming 
amount of peptide data, which can be generated using the MuDPIT method. Therefore 
the use of purification techniques, such as TAP, are extremely beneficial when 
determining specific protein interactions or looking for post-translational modifications 
(Pavelka et al., 2008).  
Determining protein-protein interactions in large protein complexes is key in 
understanding the function of each constituent, as well as determining the regulatory 
mechanisms for the complex as a whole. The success of MuDPIT for the identification of 
protein-protein interactions is often established during preparation when the complex 
protein samples, such as cell lysates, are subjected to digestion with proteolytic enzymes 
to produce fragments of the full-length proteins. Meticulous sample preparation to avoid 
the “junk-in, junk-out” digestion of the protein mixtures for MS analysis is a very 
important step. Preparation begins with solubilization using 8M urea followed by 
reduction and alkylation. Since the enzymes used to generate the digested peptide 
fragments have specific cleavage sites, the fragments created terminate with precise 
amino acid sequences. One of the most common proteolytic enzymes used is trypsin, 
which cleaves proteins at the C-terminal side of arginine and lysine residues. The 
presence of C-terminal basic residues aids in peptide ionization and facilitates shotgun 
proteomics analysis (Olsen, Ong, & Mann, 2004).  In addition to trypsinization, the use 
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of a second protease such as Endoproteinase Lys-C (Lys-C) has been found to increase 
the number of peptides identified and improve overall sequence coverage than just using 
trypsin alone (Florens & Washburn, 2006). This in turn directly impacts the number of 
unique proteins identified following MS output and data base searching through matching 
of experimentally and theoretically derived fragments. 
Prior to using mass spectrometry, resolution of proteins in complex samples was 
achieved through a lengthy separation process. SDS-PAGE and liquid chromatography 
had been used for protein separation traditionally, however each method has limitations 
for resolution of low abundance proteins, proteins of extreme size or pH, and extremely 
hydrophobic proteins (Gygi, Corthals, Zhang, Rochon, & Aebersold, 2000). SDS-PAGE, 
which separates proteins based on their relative size as they migrate through a solid gel 
while exposed to an electrical charge, achieved the best separations in conjunction with 
prior separation by isoelectric focusing, which separates proteins according to their 
individual pIs. This two dimensional electrophoresis (2DE) method also requires staining 
and removal of proteins isolated in the gel, making this method both time consuming due 
to the need to excise individual spots of protein from the gel and limiting in the number 
of low abundance proteins that could be identified since spots of proteins present in low 
quantities would not be as apparent on the stained gel (Fournier, Gilmore, Martin-Brown, 
& Washburn, 2007; Gygi et al., 2000).  
To improve the separation of the peptides in complex samples of limited quantity, 
a two dimensional liquid chromatography method using a capillary silico tubing was 
coupled sequentially to the mass spectrometer (Link et al., 1999; Washburn et al., 2001). 
The two dimensions involved in separation are a reverse phase (RP) of C18 resin 
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followed by a strong cation exchange (SCX) resin. This allowed for almost complete 
separation of the components in the sample using an incrementally increasing salt 
concentration through the run. The addition of a second RP following the SCX further 
improved the separation and increased the number of resolved peptide fragments exposed 
to MS analysis and potential detection in the subsequent database inquiry (Florens & 
Washburn, 2006).  
The final step of protein identification (and the most computationally expensive) 
in MuDPIT involves the comparison of experimentally obtained peptides to a collection 
of predicted or theoretically derived peptide sequences in a database (Keller, Nesvizhskii, 
Kolker, & Aebersold, 2002). There are several important parameters programmed into a 
database search that can determine whether a peptide match is assigned or not. These 
include the type of proteolytic enzyme used for sample digest and whether partially or 
fully digested; intentional and suspected modifications such as acetylation, 
carbamylation, methylation, phosphorylation, and ubiquitination; limits for acceptable 
peptide size and cross-correlation (e.g. Xcorr in SEQUEST) or statistical matching score 
to an in silico derived peptide; and high and low limits for false discovery rates (FDR).   
One key to obtaining correct protein identifications in MuDPIT data analysis is 
the calculation of FDRs which is the anticipated proportion of peptide to spectrum 
matches (PSM) identified incorrectly within a global collection of acquired PSMs 
(Nesvizhskii, 2010). Importantly, the individual PSMs are subject to a statistical 
calculation called a posterior probability which is an estimate of the correctly identified 
PSMs in a collection of peptides with similar database search scores (Nesvizhskii, 2010). 
Firmly setting the FDR limits helps to define the PSMs, which are considered statistically 
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valid based on the available parameters and experimental spectra obtained if they fall 
within the constraints set. This validation of the PSMs contributes to the determination of 
true versus false peptide identifications and is ultimately how protein identifications in 
complex MS/MS data analysis are established.  Due to the importance of determining 
accurate protein identifications for a collection of spectra, each individual PSM is first 
assigned a single spectrum confidence score which ranks them based on the similarity 
between the experimental spectra acquired by the MS/MS and the theoretical database 
spectrum (Nesvizhskii, 2010). The ranking is determined by converting each individual 
score into a p-value or E-value depending on the database search software used. 
These measures can then be used in calculating the FDR using several methods 
(Nesvizhskii, 2010). Two are discussed here as they relate to data analysis performed in 
this work. The first method employs the use of Target-Decoy database  compare acquired 
MS/MS spectra to a protein database containing target protein sequences for the 
experimental dataset, as well as a decoy set of protein sequences generated by using 
random or reversed sequences of the target proteins of the same size (Elias & Gygi, 2007; 
Nesvizhskii, 2010).  
The calculation for FDR simply is: False Positive IDs / total False Positives +True 
Positives at a pre-determined score cutoff. This method is commonly used for FDR 
estimates and is the method contained in our Proteome Discoverer software. One of the 
drawbacks of this method of calculating FDR is its simplicity. For example, this 
calculation for FDR does not take into account the lack of complete decoy sequences for 
post-translational modifications and potential chemical modifications (Nesvizhskii, 
Keller, Kolker, & Aebersold, 2003).   
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The second strategy for determining the FDR is a mixed model method, which 
contains a more advanced FDR calculation by considering additional parameters beyond 
just the false positive ratio such as the database search scores and other properties of 
assigned identities to peptides (Nesvizhskii et al., 2003). Briefly, this method estimates 
the error rate of individual peptide identifications by selecting the most likely peptide or 
best match from the target database and computing a posterior probability using data 
from two separate algorithms, the expectation maximization (EM) and the mixture 
estimation algorithm(Choi & Nesvizhskii, 2008; Keller et al., 2002; Nesvizhskii, 2010). 
The EM algorithm distinguishes correctly assigned peptides from false positive results 
using the distribution of search scores and other parameters while the mixture estimation 
algorithm incorporates the decoy dataset in estimating the false PSMs (Nesvizhskii, 
2010). The resulting probabilities are then used to filter the PSMs at a predetermined 
FDR. This method allows for a more accurate and reliable overall FDR derived from 
robust posterior probabilities of individual PSMs (Nesvizhskii, 2010). This model is used 
in many newer analysis software packages including Scaffold™ (aka Scaffold), which 
was utilized in part for MS/MS data analysis in this current work.  Additionally, this type 
of calculation is now included in the module Percolator in Proteome Discoverer. 
Unfortunately, we have been unable to employ Percolator since it is implemented within 
Proteome Discoverer as a 32-bit program and the dataset that we have generated are 
larger than 2GB, which exceeds the program parameters. 
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METHODS AND MATERIALS 
I. Preparation of whole cell lysates following MG132 treatment 
Untagged strains of Saccharomyces cerevisiae wild type BY4741, and derived 
deletion strains containing rtr1∆, erg6∆, or rtr1∆erg6∆ were cultured on YPD (10% 
Yeast Extract, 20% Peptone, 20% Dextrose) medium in liquid or agar plates at 30⁰C. 
After 3 days growth, liquid pre-cultures were initiated by inoculating 25ml of YPD broth 
with a single colony for each strain. Cultures were grown overnight at 25⁰C with shaking 
at 150-200rpm. The growth phase of each culture was evaluated by measuring the optical 
density (OD) at 600nm using a Bio-Rad spectrophotometer by first diluting the sample to 
approximately OD600 ≈1 in 200ml of YPD. Yeast cells were allowed to recover for 2 
hours before beginning MG132 treatment experiment.  
During recovery, 2.4mg of MG132 was resuspended in 1ml DMSO (Sigma Cat. 
No.D4540) for a stock concentration of 5mM. A working solution of 500µM MG132 
(Calbiochem Cat. No. 474790-1MG) was prepared just prior to spiking into cultures by 
diluting 5uL stock into 45µL DMSO. Following the recovery period, all four cultures 
were split into two 100ml volumes which were designated for MG132 treatment or 
untreated. Th0e cultures were then spiked with 10µL MG132 or DMSO control.  
Treatment was stopped after 3 hours by harvesting all cultures in the same order 
in which they were treated. OD600 values of the harvested cultures ranged between 4.4 
and 5.4. Collected samples were centrifuged (2 x 50ml centrifuge conicals) at 10,000rpm 
for 5 minutes at 4-6°C. The supernatants from all 8 treatment conditions were discarded 
and the pellets were frozen at -80⁰C.  
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Cell pellets were thawed completely and each treatment was combined into one 
conical tube and mixed thoroughly. Combined pellets from each treatment were aliquoted 
into 2 microcentrifuge tubes and one aliquot of each was frozen at -80⁰C for later studies, 
whereas the other aliquot was washed with 250ul TAP Lysis Buffer (350mM NaCl, 
40mM Hepes, 10% Glycerol, 0.1% tween-20, 0.5mM DTT, and 1X yeast protease 
inhibitors). After adding the lysis buffer, lysis was performed by vortexing using 
approximately 250µl of glass beads (0.5mm, Cat. No. 11079105, Biospec Products, Inc.) 
in a Disruptor Genie (Thermo-Fisher) at 4⁰C for 20 minutes. The samples were 
centrifuged for 10 minutes at 14,000rpm at 4⁰C in an Eppendorf 5430R centrifuge. The 
clarified supernatants were then transferred to clean centrifuge tubes. Protein 
concentrations of each sample were determined using the Bicinchoninic (BCA) Protein 
Assay (Pierce, Cat. No. 23225). Protein concentrations were calculated by comparing 
1:100 dilutions of each sample in duplicate to a standard curve created with known 
concentrations of bovine serum albumin. Samples (50 µg of total protein) were diluted 
with 4X SDS-PAGE loading dye and vortexed for 5 seconds. To ensure that no residual 
sample remained in the tube cap or on the sides of the tube, each sample was centrifuged 
for 1 minute at 14,000rpm in Eppendorf 5424 microcentrifuge. Samples were boiled for 5 
minutes in a dry heat block at ~100⁰C, vortexed and centrifuged again and were then 
loaded onto 10% SDS-PAGE gels (40% polyacrylamide, 1M Tris-HCl, pH 6.8, 10% 
ammonium persulfate, 10% SDS, and 8µl TEMED) with molecular weight standards 
loaded onto adjacent wells of the gels (5µL of Precision Plus protein dual color 
standards) Bio-Rad, Cat. No. 161-0374). Electrophoresis of gels was carried out at 175V 
for 1hr in 1X Tris-Gly-SDS Running Buffer (Bio-Rad Cat. No. 161-0732).  The WT 
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(BY4741) and rtr1∆ samples were loaded on one gel and the erg6∆ and erg6∆ rtr1∆ 
samples were loaded on a second gel. 
II. Western Blot Analysis  
Following SDS-PAGE, the stacking gel was removed and the gels were 
transferred to nitrocellulose membranes (Bio-Rad, Cat. No. 162-0115) overnight in 
Transfer Buffer (5.8g Tris-HCl, 2.9g Glycine, 100ml Methanol, 3.75µL 10% SDS) at 
30V with an ice pack to prevent overheating during transfer. After overnight transfer, the 
nitrocellulose membranes were removed from the transfer apparatus, marked on the gel-
facing side and placed in 5 % milk Blocking Buffer (5 grams dry milk in Tris-buffered 
Saline (TBS)) for approximately 8 hrs. Prior to incubation of the membrane with primary 
antibody, each membrane was cut in half horizontally just below the 75 kDa standard 
mark so two antibody probes could be used on all samples loaded. The top half of the 
membrane was incubated overnight at 4⁰C in 1:1000 dilution of anti- serine 5 
phosphorylated CTD (Clone H14, Covance, Table 3) in 5% milk blocking buffer. This 
antibody is specific for the largest protein subunit in RNAPII, Rbp1. The bottom half of 
the membrane was incubated overnight with 1:1000 anti-Pgk1 (Life Technologies) as a 
loading control for each experimental sample. Pgk1 stands for phosphoglycerate kinase 1 
and was chosen as a loading control because it is a constitutively expressed protein and 
should be in high concentration for each experimental sample and would confirm similar 
protein loading for each sample. Primary antibody solutions were removed the following 
day and membranes were washed 3 x 5 minutes each in TBS. Secondary antibody were 
prepared as 1:5000 dilutions in TBS. The Rpb1 secondary antibody used was peroxidase 
conjugated anti-mouse IgM (Sigma) and the secondary antibody used for Pgk1 was 
30 
 
peroxidase conjugated anti-mouse IgG (GE Healthcare). After incubating for 1 hr at room 
temperature the secondary antibody solutions were removed and the membranes were 
washed 3 x 5 min in TBS. Visual detection of the reaction products was done using the 
ECL HRP kit (GE Healthcare Cat. No. RPN2133) according to the manufacturer’s 
instructions and images were taken using the FLA 5000 Scanner (Fuji) at 473nm using a 
LPB filter.  
Antibodies and titers used for additional Western blot analyses are presented in 
Table 3. Procedures are as described for all Western blots with modifications to 
incubation times from 4hrs to overnight for primary antibodies as time allowed. 
Table 3.  Antibodies used for Western Blot analysis 
Antibody Name Mfr Secondary Antibody Titer Diluent 
Anti-Serine 2 
RNAPII CTD 
Neoclone Anti-Mouse IgM 1:500 TBS 
Anti-Serine 5 
RNAPII CTD 
Covance Anti-Mouse IgM 1:500 5% Milk 
Anti-Serine 7 
RNAPII CTD 
Dirk Eick Anti-Rat IgG 1:250 5% Milk 
Anti-Tyrosine 1 
RNAPII CTD 
Chromotek Anti-Rat IgG 1:1000 TBS 
Anti-Pgk1 Life Technologies Anti-Mouse IgG 1:1000 5% Milk 
Anti-Rpb4 Neoclone Anti-Mouse IgG 1:1000 TBS 
Anti-CBP Santa Cruz Anti-Goat IgG 1:1000 5% Milk 
 
III. Transformation of S. cerevisiae deletion strains for C-terminal tagging of 
Rpb3 
A frozen sample of bacterial stock (pAM108) containing the pBS1539 plasmid 
was directly inoculated into LB-Ampicillin (AMP) media (10mL) and incubated 
overnight at 37⁰C with shaking. Cell lysis and isolation of the plasmid were performed 
following the procedure found in QIAprep Miniprep Handbook (12/2006) using a Qiagen 
Miniprep isolation kit (Qiagen Cat. No.  27106). In brief, the bacterial culture was 
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centrifuged for 10 minutes at 5400 x g at 4⁰C after transferring cells to a 15mL conical 
tube. The supernatant was removed and the cell pellet was drained over a paper towel for 
5minutes The packed cell pellet was resuspended in 250µL of Buffer P1until no visible 
clumps were present and then transferred to a micro centrifuge tube. Buffer P2 (250µL) 
and Buffer N3 (350µL) were added sequential with mixing by inversion after each 
addition. 
 Following centrifugation (17,900xg for 10 minutes at room temperature), the 
supernatant was decanted into a QIAprep spin column and placed into a clean micro 
centrifuge tube to collect the flow through. The spin column with collection tube was 
then centrifuged for 1 minute at 17,000xg at room temperature. The flow through was 
discarded and the silica gel membrane in the column was washed with 0.75mL of Buffer 
PE by centrifuging for 1 minute at 17,000xg at room temperature. The column was 
centrifuged a final time after discarding the flow through and then transferred to a clean 
micro-centrifuge tube for collection of final isolation product. Buffer EB (50µL) was 
added to the column and incubated for 1 minute. The column was centrifuged for 1 
minute at 17,000xg at room temperature. Spectrophotometric analysis (A260/A280) of 
the final sample was done to determine the concentration of the isolation product using 
the dsDNA method on the Eppendorf Biophotometer Plus using a sterile, disposable 
cuvette after using an aliquot of Buffer EB as a blank. The stock plasmid DNA was then 
diluted to obtain a 100 pg/µL concentration for the PCR amplification protocol.  
The isolated plasmid, pBS1539, was used as a template for a standard PCR method set in 
a total reaction volume of 100 µL. Table 4 shows the reaction components and volumes 
of each. Table 5 details the thermocycler parameters used for each amplification done. 
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Three total reactions were necessary to obtain enough purified PCR products containing 
the TAP construct for the yeast transformations. Ideally, 1 µg of the purified disruption 
cassette is needed per strain (Baudin, et.al. 1993), however at total of 1.8 µg was 
recovered and split between the two transformation reactions. 
Table 4. Details of PCR reaction mixture  
Component Volume added Concentration 
DNase-free Water 69 µL N/A 
5X GoTAQ Buffer 20 µL N/A 
dNTPs 3 µL N/A 
Rpb3 TAP F primer 3 µL 10 µM 
Rpb3 TAP R primer  3 µL 10 µM 
DNA pBS1539  1 µL 100 pg/µL 
Go Taq 1 µL N/A 
Final Reaction Volume 100 µL  
 
Table 5. Details of PCR parameters 
Cycle Temperature (°C) Time 
Initial Melting 94 2 min 
1-30 
94 15 sec 
52 30 sec 
72 2 min 
Final Annealing 4 Hold until retrieved 
 
Following amplification, completed reaction mixtures were loaded onto a 1.5% 
agarose gel (1.5g Agarose, 100mL TBE) with the addition of SYBR green (5µL/100mL) 
for visual detection. Samples and a 1kB DNA molecular weight markers were 
electrophoresed for 30 minutes at 140V. Once electrophoresis was completed, the gel was 
placed in a Chemidoc XRS molecular imager to collect an image of the PCR product 
bands in the gel using Quantity One software. The bands were cut from the gel and 
purified using Promega DNA purification kit (Promega Cat. No. A2492). 
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Excised bands were placed in 1.5mL micro centrifuge tubes and gels were 
dissolved at 65⁰C after the addition of 10µL Membrane Binding Solution. Membrane 
Binding Solution (200µL) was added to the dissolved gel and then transferred to a mini-
column and subjected to vacuum filtration to bind amplified PCR products. Following 
filtration, the membrane was washed twice with 700µL and 500µL of Membrane Wash 
Solution, respectively. The mini-column with bound DNA was then transferred to a 
collection tube and centrifuged for 5 minutes at 16,000xg. The mini-column was eluted 
with 50µL of nuclease-free water by centrifuging for 1 minute at 16,000xg. 
Spectrophotometric analysis to determine the purity and concentration of the final eluted 
DNA was determined as described above section and stored at -20°C for later use.    
Incorporation of epitope or fusion tags is an efficient way of facilitating the 
purification of target proteins or protein complexes (Baudin et al., 1993; Puig et al., 2001; 
Puig et al., 1998). Transformation of yeast strains stimulates uptake of a specific 
disruption cassette and integration into the yeast chromosome of interest by homologous 
recombination.  C-terminal tagging by homologous recombination allows for the 
purification of protein complexes under native conditions (Puig et al., 2001). In order to 
produce TAP tagged cultures for this study, pre-cultures (5mL) of yeast strains deleted 
for the ERG6 gene (yAM153) and RTR1 and ERG6 (yAM154) genes were grown in YPD 
media overnight with rocking at 30⁰C. Yeast cultures (25ml) were inoculated at OD600 
≈0.25 and grown for 6 hours before transferring each a portion of each culture to 15mL 
conicals (2 x 10mL aliquots for each genotype). The remainder of the initial cultures was 
discarded. 
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The transformation was performed by first collecting the cells by centrifugation at 
3000 rpm for 5 minutes at 4⁰C. A separate transformation mixture was prepared to create 
both erg6∆ and rtr1∆ erg6∆ transformation competent cells. The supernatants were 
poured off and the packed cell pellets were resuspended in 100µl fresh TE-LiOAc 
(100µL of 10X 0.1M Tris-HCl, 0.01M EDTA, pH 7.5 and 100µL of 1M LiOAc, pH 7.5 
diluted with 800µL sterile water).  The cells were allowed to equilibrate while the 
remaining reaction components were prepared. Approximately 0.9µg (in 45µL) of 
amplified PCR product containing the TAP tag construct was added to each cell 
suspension and vortexed. Salmon sperm DNA (ssDNA) at a concentration of 10 mg/ml 
was boiled for 10 minutes and kept in ice until ready for use. Following addition of the 
disruption cassette to each cell suspension, 5 µL of ssDNA was added and vortexed. One 
aliquot of erg6∆ competent cells was set up as a negative control with addition of only 
ssDNA. To complete the mixture, 600µL of fresh PEG-LiOAc (For 10mL: 8ml 50% PEG 
3350, 1mL 10x stock of TE, and 1mL 1M LiAOc) was added and vortexed thoroughly 
and mixed by inverting each tube several times. The mixtures were then heat shocked at 
42⁰C for 20 minutes. Following overnight incubation at 4⁰C, transformed cells were 
collected by centrifugation for 1 minute at 4000xg and supernatants were discarded. Each 
cell pellet was resuspended in 200 µL sterile water and spread onto pre-warmed YNB 
URA- agar plates using glass beads. The yeast agar plates were incubated at 30⁰C until 
visible colonies began to appear in ~3-4 days.  
To ensure that the TAP tag was incorporated by homologous recombination (i.e. 
integrated) into the erg6∆ and erg6∆ rtr1∆ strains, Western blots were done to confirm 
the expression of the Rpb3-TAP fusion protein. Each colony that grew on the YNB 
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URA- plates was considered a potential transformant and was restreaked for isolation 
onto a fresh YNB URA- plate. After incubating for 2 days at 30⁰C, 25ml of YPD media 
was inoculated with a single colony from the restreak of each of the original colonies and 
incubated overnight at 30⁰C. Each sample was centrifuged for 10 minutes at 4000xg at 
room temperature and whole cell lysates were prepared as described previously for the 
MG132 small scale study. Samples were run on 10% SDS-PAGE with 2x loading dye 
(15uL lysate + 15uL 4x loading dye) for 1hr at 200V. The separated protein mixtures 
were then transferred to nitrocellulose membranes for 3 hrs at 50vV by western blotting 
in transfer buffer. The nitrocellulose membrane was removed and marked on the gel 
facing side and blocked in 5% milk blocking buffer for 30 minutes. The blocked 
membrane was probed using Anti-CBP (Thermo Fisher Cat. No. CAB1001), which is 
specific to the calmodulin binding peptide portion of the TAP tag that would be present 
as part of the TAP tag at the C-terminus of Rpb3 if the tag was truly incorporated into the 
Rpb3 locus in the yeast genome. The primary antibody was diluted at 1:1000 in 5% milk 
blocking buffer and incubated with the membrane overnight. The primary antibody 
solution was removed the next day and the membrane was washed 3 x 5 minutes with 1x 
TBS. Peroxidase conjugated anti-rabbit IgG (GE Healthcare Cat. No. NA934A) was used 
as the secondary antibody. The secondary antibody was diluted 1:1000 in TBS and 
incubated with the membrane for 1 hr. After incubation, the membrane was washed in 
TBS 3 x 5 minutes. As with the previous blot, the ECL HRP (GE Healthcare Cat. No. 
RPN2133) detection was used and the membrane was imaged using the FLA 5000 
scanner.   
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TAP Method 1: Liquid Nitrogen Freezing Lysis  
Before a large scale proteosomal inhibition study was begun, a pilot large scale 
purification using the new TAP-tagged S. cerevisiae mutant strains Rpb3-TAP erg6∆ and 
Rpb3-TAP erg6∆ rtr1∆ was performed to confirm that the cells would be suitable for the 
large scale MG132 treatment study. Pre-cultures (25 mL) of the newly created strains 
were inoculated and grown in YPD media overnight at 30⁰C. The OD600 of each culture 
was used to determine the amount to add a 3L YPD batch size to reach an OD600 
between 4-6 during an overnight growth. The following day, OD600 determinations were 
obtained and the Rpb3-TAP erg6∆ strain was slightly at 6.2 and the TAP procedure was 
begun. The Rpb3-TAP erg6∆ rtr1∆ growth was still less than optimal after allowing an 
additional 2 hrs growth with OD600 3.0. Both cultures were harvested, centrifuged at 
4000rpm for 10 minutes at 4⁰C and then washed with MilliQ Water. Following 
centrifugation and removal of the supernatant, the packed cell pellets were frozen until 
the lysis procedure was performed the following day.  
At this point, after observing that the Rpb3-TAP erg6∆rtr1∆ strain had a 
significantly lower growth rate than the Rpb3-TAP erg6∆, a growth curve study was 
done to get a better estimate of lag time needed for recovery following inoculation and 
between the two cultures. Small 25 mL cultures of each strain were inoculated at 
OD600~ 0.5. Cultures were incubated at 30⁰C for the duration of the study except when 
samples were removed. Samples (1 mL) of each were removed once every hour for 8 hrs 
and the OD600 result was recorded.  
The TAP procedure for method 1 was performed by resuspending thawed packed 
cell pellets in TAP Lysis Buffer at ratio of approximately 10:1 of buffer to cell pellet 
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(vol/vol). The cell mixture was added to a liquid nitrogen bath using an 18-gauge needle 
and syringe and ground into a fine powder by hand using a mortar. Crushed cells were 
subsequently transferred to a stainless steel Waring blender to be ground with dry ice 
pellets. When the frozen cell slurry was completely crushed into a fine powdery mixture, 
it was transferred to another stainless steel canister and placed in a water bath to facilitate 
thawing. DNAseI (100 IU, Sigma Cat. No. D4623) and heparin (~300µg, Sigma Cat. No. 
H3393) were added to the cell lysate, followed by incubation for 10 minutes to solubilize 
the DNA/chromatin-associated RNAPII complexes before beginning the 
immunoprecipitation steps of the procedure. The extracts were collected by 
centrifugation at 14,000xg for 30 minutes at 4⁰C.  
Following clarification, the lysate was transferred to a beaker for 
immunoprecipitation steps and treated with 200 µL of washed IgG Sepharose resin (GE 
Healthcare Cat. No. 17-0969-01).  The purpose of the IgG resin is to purify the RNAPII 
associated proteins through interaction of the Protein A section of Rpb3-TAP tag with the 
resin. The mixture was incubated overnight on a stir plate at 4⁰C and transferred to a 30 
mL Bio-Rad Econoprep column for separation by gravity flow. The retained resin was 
washed with 30 mL TAP Lysis Buffer and again with 3 mL of TEV Cleavage Buffer (10 
mM Tris, pH 8, 150 mM NaCl, 0.1% IGEPAL, 0.5 mM EDTA, 10% Glycerol) and the 
flow through was saved until the purification was completed. The resin was resuspended 
with 1 ml of TEV Cleavage Buffer and transferred to a clean micro centrifuge tube. The 
resuspended resin was then treated with 10µL AcTEV protease (Invitrogen Cat. No. 
12575-023) and incubated overnight at 4⁰C. The suspension was returned to the same 
Econoprep column the next day and the TEV cleavage products were collected in a 15 
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mL conical tube by gravity flow. The tube used for TEV cleavage reaction and the 
column were  washed with Calmodulin Binding Buffer (10 mM Tris, pH 8, 1 mM 
magnesium acetate, 1 mM imidazole, 2 mM calcium chloride, 10% glycerol) and 
combined with the TEV cleavage product elution. The eluate was then treated with 
500µL of washed Calmodulin Sepharose (Stratagene Cat. No. 214303) and incubated for 
3 hrs at 4⁰C on a rotating wheel. This step utilizes the affinity of calmodulin located on 
inserted TAP tag to bind to immobilized Calmodulin to further purify the tagged protein 
and any associated proteins. Following incubation, the suspension was transferred to a 
clean Bio-Rad Econoprep column for separation by gravity flow. The retained resin was 
washed with 30 mL of Calmodulin Binding Buffer. The final products were eluted by the 
addition of 1 mL volumes of Calmodulin Elution Buffer (10 mM Tris, pH 8, 300 mM 
NaCl, 1 mM magnesium acetate, 1 mM imidazole, 1 mM EGTA, 10% glycerol) x 5. 
Elutions were labeled E1-E5 and stored at -80⁰C until SDS-PAGE analysis was done. 
Protein samples were separated on 10% SDS-PAGE for 1hr at 150V and visually 
detected using silver stain procedure. 
TAP Method 2: Bead Beating Lysis 
Due to incomplete lysis of the cells using the liquid nitrogen TAP method and low 
protein yields in the extract, a comparison to a different lysis method using glass beads in 
an aluminum bead beater canister. Rpb3-TAP erg6∆ and Rpb3-TAP erg6∆ rtr1∆ strains 
were grown overnight at 30⁰C in 3L of YPD media to an OD600 >8. Half of each culture 
was lysed using both methods. The liquid nitrogen TAP method was performed as 
described above and the cells used for the Bead Beating method were resuspended in 
200-250mL TAP Lysis Buffer and added to the bead beating canister. Glass beads were 
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added to the canister until the liquid portion of the mixture just reached the top of the 
opening when blender cover was inserted in place. The apparatus was assembled with 
water bath attachment in place and closed tightly and inverted onto the blender base. Ice 
and water were added to the bath attachment and the beater was pulsed 10 times for 20 
seconds with a 1 minute rest between pulses. The bead slurry/lysate mixture was 
transferred to a clean beaker and the lysate was removed from the beads using a 
serological pipette. The lysate was clarified by centrifugation at 14,000xg for 30 minutes 
at 4⁰C and processed using the TAP procedure as described above.  Purified protein 
products were separated on 10% SDS-PAGE for 1 hr at 150V and visualized using silver 
staining procedure described below.  
III. Silver Staining Procedure   
In order to confirm successful purification of RNAPII and associated proteins, 
silver staining was performed on completed SDS-PAGE gels. Following electrophoresis, 
the SDS gel was placed in stain resistant container after removing stacking gel. All steps 
in the procedure were performed at room temperature. The gel was initially treated with 
100 mL Fixing Solution (30% ethanol (reagent grade), 10% acetic acid, 60% water) with 
shaking for at least 30 minutes. After discarding the fixing solution, the gel was washed 
with 100 mL of 30% ethanol (30% ethanol, 70% water) for 10 minutes with shaking. The 
ethanol was then discarded and replaced with 100 mL water for 10 minutes with shaking. 
Following the wash, 100mL of Sensitizer Solution (0.2% sodium thiosulfate in water) 
was added and incubated for 10 minutes in the dark. The Sensitizer Solution was then 
discarded, the gel was washed as above and 100mL of Silver Nitrate Solution (0.1% 
silver nitrate, 0.02% formaldehyde, 99.9% water) was added. Following a 10 minute 
40 
 
incubation in the dark the Silver Nitrate Solution was discarded appropriately and the gel 
was washed quickly (no more than 5 minutes) with water. The stained gel was then 
developed with 100mL Developing Solution (2.5% sodium carbonate, 0.05% 
formaldehyde, 0.005% sodium thiosulfate) for 2-10 minutes with shaking. Once protein 
bands were visible on the gel, the developing solution was removed and the reaction was 
quenched with 100mL of Stop Solution (0.5% glycine in water) for 10 minutes with 
shaking. Finally, the Stop Solution was removed and the gels were placed in water until 
imaged using a digital scanner.  
IV. MG132 treatment of TAP-tagged S. cerevisiae mutant strains 
 A small scale comparison of MG132 treatment to untreated controls was 
performed using newly created Rpb3-TAP strains to see if a treatment effect was evident 
before proceeding to the large scale study. Pre-cultures of both Rpb3-TAP erg6∆ and 
Rpb3-TAP erg6∆ rtr1∆ strains as well as the untagged parent strains of each were 
inoculated and grown overnight at 30⁰C in 100mL of YPD media. The OD600 was 
assessed the following day and the amount of cells needed to inoculate 200mL of media 
at an OD600 equal to ~1 was determined. Following a 2 hr recovery time, each culture 
was split into 2 flasks, with 100ml in each. One culture was treated with 50µM MG132 
and the other with DMSO control, harvested after 2 hr treatment period, and then lysed as 
described above (See Section I of Methods for details). Protein concentrations were 
determined by BCA using known concentrations of bovine serum albumin to make a 
standard curve. Samples were separated on a 10% SDS-PAGE and subjected to western 
transfer as described to compare the status of the RNAPII CTD phosphate modifications 
between experimental groups.   
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 Rpb3-TAP tagged yeast strains were inoculated into large 3L flasks containing 
YPD media and grown overnight. OD600 was determined and the amount of cells needed 
to inoculate the study cultures at OD600 ~ 4. Two 1.5L of YPD media were inoculated 
for each strain and labeled MG132 Treated and Untreated. The cells were placed at 30⁰C 
for 2 hrs to allow recovery growth. OD600 was checked again just prior to treatment with 
50µM MG132 or DMSO control (i.e. untreated). Each culture was then spiked with 
MG132 or DMSO as previously described and incubated for 2 hrs at 30⁰C. The TAP 
procedure was performed after harvesting of the treated and untreated cultures. 
Confirmation of purification success was accomplished using silver stains and sample 
elutions from each purification (E1 and E2) were prepared as previously described for 
MS evaluation.   
V. MuDPIT Analysis 
 Following the TAP processing, benzonase (1U/ml) was added to final elution 
products to remove any contaminating nucleic acid residues. Elutions 1 and 2 were 
combined from each TAP procedure (100µL of each) and prepared for LC/MS analysis 
by first precipitating with cold trichloroacetic acid (TCA). Prior to addition of TCA, 
200µL of 100 mM Tris-HCl was added to each sample in a microcentrifuge tube. One-
hundred microliters of TCA (Sigma Cat. No.  T6399) was then added and mixed by 
vortexing. Following overnight incubation at 4⁰C, samples were centrifuged at 14,000 
rpm for 30 minutes at 4⁰C. The supernatant was carefully removed and 500 µL of cold 
acetone was added to protein pellets in each tube and mixed by vortexing. Next, the 
samples were centrifuged at 14,000 rpm for 10 minutes at 4⁰C and the acetone wash was 
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repeated a second time as described. The visible protein pellet was then left to dry 
uncapped at room temperature 1-24 hrs. 
Air-dried precipitated protein samples were resuspended in denaturing conditions 
(8M urea in 100 mM Tris-HCl, pH 8.5). Reconstituted samples were treated for 30 
minutes at room temperature with 1.5µL Tris (2-Carboxylethyl)-Phosphine 
Hydrochloride (TCEP, Pierce Cat. No. 77720) to a final concentration of 5 mM TCEP. 
Samples were then alkylated for 30 minutes in the dark with 0.6µL of 
carboxyamidomethylate (CAM, Sigma Cat. No. 22790) to a final concentration of 10 
mM and digested overnight at 37⁰C with 0.3µL of Endoproteinase Lys-C (≥150U/mL; 
Promega, Cat. No. V1071).  The next day, the samples were diluted to 2M urea using 
90µL of 100 mM Tris-HCl and 0.6µL of 1M CaCl2 and digested with addition of 0.5µL 
Trypsin overnight at 37⁰C with shaking. Prior to loading the sample into a microcapillary 
tube and analysis by LC/MS, the approximately 100µL reaction was quenched using 1% 
formic acid (7µL) (Sigma Cat. No. F0507) and centrifuged at 14,000 rpm for 20-30 
minutes to clarify the sample.  
 Samples were loaded as previously described (Florens & Washburn, 2006). 
Specifically, prepared samples were pressure-loaded into silica microcaplillary columns 
(100µm inner diameter) containing triphasic layers of packing material (8 cm C18 
reverse phase/2 cm 5 µm strong cation exchange/2 cm C18 reverse phase) using a steel 
pressurization device (Florens & Washburn, 2006). Following sample loading, the 
column was equilibrated with Buffer A (5% Acetonitrile, 0.1% formic acid).   
 Each loaded column was placed on a Proxeon nano-liquid chromatograph (LC) in 
line with a ThermoFisher LTQ Velos linear ion trap mass spectrometer (MS) equipped 
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with a nano-LC electrospray ionization source. The application used to resolve the 
peptides in the sample mixture was a 10-step fully automated chromatographic 
separation, elution, and peptide fragmentation via collision induced dissociation (CID) 
programmed using the Thermo Xcalibur software. Chromatographic separation of the 
peptides was accomplished using elution Buffers A, B, and C sequentially, where a 
gradient shift from Buffer A to Buffer B (80% Acetonitrile, 0.1% formic acid) along with 
increasing salt concentrations in Buffer C (5-300 mM Ammonium Acetate, 5% 
Acetonitrile, 0.1% formic acid) was set up. The ten most intense/abundant spectral peaks 
recorded over a range of 400-1600 m/z were subjected to tandem MS (MS/MS) analysis 
in a data dependent acquisition.  A dynamic exclusion time of 150 seconds was set to 
allow for sampling and subsequent MS/MS analysis (fragmentation) of lower abundant 
ions.   
 The collected mass spectra were subjected to FASTA database searching using 
the SEQUEST search algorithm in the Proteome Discover software (Thermo).  A custom 
database was used for protein identification that included 5819 Saccharomyces cerevisiae 
protein sequences that were downloaded from National Center for Biotechnology 
Information genome build (downloaded file on 04-26-2011). The NCBI database also 
included other common contaminants (i.e. keratin and proteinases) whose protein 
sequences were obtained from the common repository of adventitious proteins (cRAP) 
from the Global Proteome Machine (GPM). To estimate the FDR of each unique peptide 
identified, the reverse sequences were used in the database for decoy protein 
identification. The FDR is calculated using the following calculation: False Positive IDs/ 
Total False Positives + Total Positives at the cutoff of 2%. The peptides which have the 
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highest confidence have a 2% FDR threshold and the peptides with medium confidence 
were set with a 5% FDR. All spectra searches were done using the following parameters: 
Trypsin used for digestion; FDR threshold of 2%; Static modifications: +57 Da to 
cysteine for reduction and CAM addition to peptide mixtures; Dynamic modifications: 
+16 Da for oxidized methionine.  In addition to the above, searches for ubiquitin and 
phosphorylation post-translational modification events were done with dynamic 
modifications of +114.1 and +80 Daltons respectively. Further parameters for additional 
ubiquitination site searches using X!Tandem through Scaffold software were Pyro 
Glutamic Acid (-18 Da), Pyro Cmc (-17 Da), N-terminal acetylation (+42 Da) and 
Methionine cleavage (-131 Da). 
VI. Malachite Green Phosphate Assay 
A phosphatase assay was performed to determine if a recombinant Rtr1 enzyme 
was active on a synthetic peptide substrate with the sequence 
“MPEQKITEIEDGQDGGVT*PYS” where T* is phospho-threonine. The assay is a 
colorimetric method which uses the complex formation between malachite green, 
molybdate and free orthophosphate and is read at a wavelength of 620 nm. The amount of 
colorimetric change in the sample is directly proportional to the amount of phosphate 
released during the phosphatase reaction. Multiple concentrations of the GST-Rtr1 were 
used to test a fixed amount of substrate. 
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RESULTS 
I. The effects of MG132 treatment on RNA Polymerase II phosphorylation in 
RTR1 deletion strains 
As discussed previously, the use of proteasome inhibition has been used by 
several investigators to study protein degradation by the proteasome (W. Kim et al., 
2011; D. H. Lee & Goldberg, 1996). The use of untagged strains to investigate the effect 
of proteasome inhibition on RNAPII recycling was done prior to proceeding to a large 
scale MG132 treatment experiment. The Western blot analysis seen in Figure 7 shows a 
high molecular weight product collecting in the top of several wells (4, 6 and 8). This is 
consistent with other findings (W. Kim et al., 2011; D. H. Lee & Goldberg, 1996; Liu et 
al., 2007) suggesting that treatment of the mutant strains with the proteasome inhibitor, 
MG132, results in the accumulation of the RNAPII with S5-P CTD in the whole cell 
extract.  This accumulation is exacerbated upon deletion of RTR1 (see Figure 7, lane 8, 
marked with red asterisk).     
46 
 
 
 A small scale MG132 treatment experiment was performed prior to the large scale 
study using the newly transformed mutant S. cerevisiae strains. In addition to providing a 
preview to the large scale results, purification products were subjected to immunoblot 
analysis for several CTD modification states. Following treatment as previously 
described, MG132 treated and untreated cells were lysed in TAP Lysis Buffer using glass 
beads and disruptor genie. Protein concentrations were measured using BCA and 
calculated against a bovine serum albumin standard. Four 12% SDS-PAGE gels were 
prepared and 50 µg of each sample was denatured in 2X SDS loading dye for 10 minutes 
at 100⁰C. Following electrophoresis (1.5hrs at 150V in Tris/Gly/SDS running buffer), 
western transfer to nitrocellulose membranes was performed overnight as described. The 
following day, each membrane was cut horizontally at the 100 kDa mark and each half 
Figure 7. Comparison of RNAPII Serine 5 phosphorylation using Western blot of four 
strains of S. cerevisiae both MG132 treated and untreated. Whole cell extracts were probed 
with anti-phosphorylated Serine 5 CTD and Anti-Pgk1antibodies. Accumulation of 
phosphorylated S5 CTD is seen in MG132 treated cultures of both mutant strains (lanes 6 
and 8) when compared to the untreated (5 and 7). The high molecular weight products 
containing phosphorylated S5, denoted by the red asterisk, can be seen collecting at the 
interface between the stacking and resolving gel in lane 8.   
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probed with a different primary antibody. 
Figure 8. Comparison of RNAPII Tyrosine 1 phosphorylation using Western blot analysis of 
MG132 treated and untreated yeast strains. Whole cell extracts were then treated with Anti-
Tyrosine 1 phosphorylated CTD of Rpb1 and Anti-TAP antibody. There was no apparent detection 
of Tyrosine 1 phosphorylation in any of the samples tested. Tap tagged strains as expected showed 
reaction to TAP antibody while the untagged strains did not react to the fusion tag specific antibody.  
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Figure 9. Comparison of RNAPII CTD Serine 2, 5, and 7 phosphorylation Western blot analysis 
of MG132 treated and untreated yeast strains. Whole cell extracts (50ug from each condition) 
were incubated with antibodies towards different CTD phosphorylation states of the Rpb1 CTD 
and protein loading controls. Shown from top to bottom are Anti-Serine 2 phosphorylated CTD, 
Anti-Pgk1, Anti-Serine 5 phosphorylated CTD of Rpb1, Anti-Serine 7 phosphorylated CTD of 
Rpb1 and Rpb4. There was no reaction to the Serine 2 phosphorylated CTD in any of the treated 
and untreated samples, whereas the loading control showed similar levels of the Rpb4 in all 
samples. Tap tagged mutants showed a greater amount of accumulation of the Serine 5 
phosphorylated CTD and Serine 7 phosphorylated CTD than the untagged strains. The difference 
in the abundance of Rpb4 does not appear to be a consequence of the proteins being tagged and 
untagged or treated vs untreated. 
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II. Generation of S. cerevisiae strains Rpb3-TAP erg6∆and Rpb3-TAP  
erg6∆ rtr1∆ TAP tag through homologous recombination 
The use of rapid purification methods has been shown to be invaluable to study 
protein interactions involving large multiple subunit complexes such as RNAPII 
(Washburn, 2008). In order to study the interaction between the RNAPII complex and 
proteasomal activity, the use of TAP-tagged mutant S. cerevisiae yeast strains with the 
single deletion of ERG6 and a double deletion of ERG6 and RTR1 was required to ensure 
the strains are sensitive to proteasomal inhibition. The first step in transformation 
involved the amplification of a specific PCR product that contained the disruption 
cassette.  The 5’ and 3’ ends of this PCR DNA fragment each included65bp of sequence 
identifying with the sequences flanking Rpb3 gene and a selectable marker (URA3) 
amplified from the plasmid (pBS1539).  
The erg6Δ and erg6∆ rtr1∆ strains were successfully transformed with the 
insertion of the C-terminal TAP tag at the endogenous locus of the Rpb3 gene.  The 
single mutant strain, Rpb3-TAP erg6∆, developed two single colony transformants that 
were each grown up and subjected to western blot analysis to confirm insertion; whereas 
five transformants were isolated in the double mutant, Rpb3-TAP erg6∆ rtr1∆. Figure 10 
confirms incorporation of the TAP tag using an Anti-Calmodulin Binding Protein (αCBP) 
antibody following western transfer. 
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III. Isolation of RNA Polymerase II complexes following MG132 treatment from 
wild-type, RTR1 deletion, ERG6 deletion, and RTR1/ERG6 double deletion 
strains 
A test purification of one colony from both the single deletion (Rpb3-TAP erg6∆) 
and double deletion (Rpb3-TAP erg6∆ rtr1∆) strains was performed to ensure that the 
strains would be suitable for large scale MG132 treatments. Figure 11 shows 
representative silver stains of the elution products for TAP procedures from both strains. 
Elutions 1 and 2 from each procedure illustrate the abundance of RNAPII products with 
most of the twelve subunits visible. Elutions 1 and 2 from each colony contained the 
highest levels of purified RNAPII. These results suggest that the TAP tagged strains are 
appropriate for further studies (Figure 11). 
Figure 10: Western blot analysis of Anti-CBP in yeast transformants isolated from YNB 
URA- agar after treatment with LiOAc and pBS1539. Two transformants were isolated from 
the erg6∆ plate and five transformants were isolated from the erg6∆rtr1∆ plate.  
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It was noted during the cell culture to test TAP isolations that the double mutant 
strain Rpb3-TAP erg6∆ rtr1∆ had a pronounced slow growth phenotype that caused 
yields of purified RNAPII to be low. In order to perform the next experiments, 
calculating growth rate was important to allow for direct comparisons to ensure equal cell 
numbers in mid-log phase of growth for MG132 treatment. Figure 12 displays the results 
of a growth curve comparison between the single deletion strain Rpb3-TAP erg6∆ and 
the double deletion strain Rpb3-TAP erg6∆ rtr1∆. The growth curve for the double 
mutant indicates a longer lag phase before exponential growth resumes. For example, at 
time point 5, the OD600 for Rpb3-TAP erg6∆ is twice that of the Rpb3-TAP erg6∆rtr1∆. 
As a consequence, comparing the two strains requires a greater inoculation volume for 
the double mutant. The doubling time following lag phase is also slowed relative to 
Rpb3-TAP erg6∆ (90 minute doubling time vs. 180 minute doubling time).  
Figure 11. Silver stain results of TAP-tagged strains of S. cerevisiae. Final elutions (E1 and E2) in both 
erg6∆ and erg6∆rtr1∆ resulted in purification of multiple protein subunits of RNAPII.  
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Due to inadequate cell lysis that was monitored through the volume of the cell 
pellet prior to and following cell lysis, we performed two different lysis procedures for 
TAP purification as described in the methods section.  The TAP lysis method comparison 
results are presented in Figure 13. Purification products from the bead beating method 
showed marked improvement in both yield and quality of final purification elutions. 
Based on these initial purification results, the bead beating lysis was the chosen method 
for use in the proteasomal inhibition study.  
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Figure 12. Growth curve comparison of Rpb3-TAP erg6Δ (aka erg6D) vs Rpb3-TAP erg6Δ rtr1Δ 
(aka erg6D-rtr1D). Both deletion strains were grown in YPD media with inoculating OD600 of 
0.5. After a 2 hr recovery time, the OD600 measurements for each strain were collected at various 
time points over approximately 8 hrs. The time point (hrs) was plotted against OD600.   
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Following treatment of the strains with the proteasomal inhibitor MG132, 
purifications were performed on lysates produced using the bead beating apparatus. The 
initial silver stain gels from the calmodulin elutions of both MG132 treated and untreated 
cells from both deletion strains are presented in Figure 14.  
Figure 13. Representative silver stains comparing yeast lysis methods prior to TAP procedure. Both 
TAP tagged deletion strains were lysed using bead beating and LN2 freeze followed by grinding.  
Samples derived from bead beating lysis show significantly more purification products with 
marginally “cleaner” preps, i.e. less contaminating keratin using the same amount of starting 
material.  
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 The resulting silver stains suggest that erg6∆rtr1∆ cells treated with MG132 have 
an apparent increased yield of RNA Polymerase II complexes following Rpb3-TAP when 
compared to the untreated erg6∆ rtr1∆. However, it is difficult to determine if the same is 
the case for the erg6∆ comparison since the samples were run on separate gels. In order 
to confirm these differences in RNAPII abundance calmodulin elutions 1 and 2 from each 
MG132 treated and untreated samples were run on the same gel and visually detected by 
silver staining (Figure 15). 
Figure 14. Silver stain results from large scale MG132 treated and untreated TAP tagged deletion 
strains. Comparing Rpb3-TAP erg6∆ MG132 treated and untreated does not show apparent 
difference in RNAPII abundance, however the MG132 treated Rpb3-TAP erg6∆ rtr1∆ elutions 
appear to have more abundant products following separation on 10% SDS-PAGE compared to the 
untreated samples.  
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 The results in Figure 15 clearly show an increase in the amount of RNAPII 
isolated from erg6∆ rtr1∆ cells following MG132 treatment. However, the treatment 
effect is not seen in erg6∆ cells alone. The data indicates that the total level of RNAPII is 
decreased in rtr1∆ cells that would support our hypothesis that RNAPII turnover rates are 
increased through proteosomal degradation following the loss of Rtr1 function.  
  
Figure 15. Comparison of elutions 1 and 2 from MG132 treated and untreated TAP tagged 
deletion strains as detected by silver stain. Relative abundance of RNAPII is greater in 
MG132 treated wells for erg∆ when comparing lanes 1+ 2 (Untreated) to lanes 3 + 4 (MG132 
treated).  When comparing erg6∆ rtr1∆ MG132 treated samples (lanes 7 + 8) to untreated 
samples (lanes 5 + 6), the effect is the same as for the erg6∆ cells with a more pronounced 
difference.  
kDa 
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IV. Identification of ubiquitination sites in RNA Polymerase II purifications 
using a two-step bioinformatics analysis 
 Analysis of post-translational modifications by LC-MS/MS has been increasingly 
used to determine regulatory roles in specific biochemical pathways or protein 
interactions. Isolating potential sites of modification through database search can be 
difficult due to the transient and reversible nature of PTMs (Farley & Link, 2009). 
Consequently, the importance of properly designing an experiment and the follow-up 
database searching and method for PSM determination cannot be understated. Methods of 
protein identification vary in the algorithms used to determine true versus false PSMs 
(See Introduction). In this present work, a direct comparison was done to investigate 
which analytical method would result in the most accurate and robust data. Proteome 
Discoverer was used in the initial database search using the SEQUEST algorithm 
identifying spectral matches. This data was then further analyzed using Scaffold software 
containing X!Tandem algorithm to both confirm and assign additional peptide 
identifications. The resulting comparison between the initial Proteome 
Discover/SEQUEST results and the two-step analysis using both Proteome 
Discover/SEQUEST and Scaffold/X!Tandem showed an increase in all RNAPII subunit 
related peptides using the two-step analysis (Table 6).  After obtaining these data, we 
proceeded to use this two- step proteomics data analysis procedure using Proteome 
Discoverer followed by Scaffold analysis.   
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Table 6. Comparison of MS/MS results using Proteome 
Discoverer/SEQUEST vs Scaffold/X!Tandem 
Protein 
Total Number of 
Peptides Identified 
through Proteome 
Discovery/SEQUEST 
Total Number of 
Peptides Identified 
through 
Scaffold/X!Tandem 
Increase 
RPB1 1746 4561 2.61 
RPB2 1051 3568 3.39 
RPB3 299 1022 3.42 
RPB4 262 615 2.35 
RPB5 212 426 2.01 
RPB6 125 242 1.94 
RPB7 31 149 4.81 
RPB8 295 428 1.45 
RPB9 151 420 2.78 
RPB10 0 40 INFINITE 
RPB11 242 495 2.05 
RPB12 179 374 2.09 
SPT5 2 12 6.00 
UBI4 17 0 0.00 
 
 The addition of polyubiquitin to lysine side chains of proteins is a post- 
translational modification that leads to their degradation by the proteasome (Liu et al., 
2007).  This degradation pathway is essential for cellular processes such as quality 
control, cell cycle regulation, transcription, protein transport and DNA repair (reviewed 
by Sorokin, Kim, & Ovchinnikov, 2009). The proteasome is a large complex consisting 
of 2 sub-complexes, 19S and 20S, which function together to recognize the polyubiquitin 
signal and catalyzes proteolytic destruction as well as other regulatory functions. The 19S 
component consists of 9 protein subunits and the 20S core particle is 14 subunit complex.  
In this current study, we were interested in determining if RNAPII degradation is 
proteasome-dependent using quantitative proteomic analysis of post translational 
modifications.    
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 We used LC-MS/MS technology to evaluate purified Rpb3-TAP isolated 
complexes from mutant strains of S. cerevisiae treated with the proteasome inhibitor, 
MG132 and compared the resulting peptide listing to untreated samples from the same 
strains. In total, five erg6Δ and four erg6Δ rtr1Δ samples were digested and subjected to 
MuDPIT analysis (see Methods section). For each strain, protein identifications including 
total PSMs were tabulated following Scaffold database searches (Tables 7-10).  
The protein identification data obtained after MuDPIT were sorted according to the total 
spectral counts (PSM) and known annotated contaminants listed in our custom FASTA 
database were removed from the final datasets. Most proteins identified by a total spectral 
count of less than 20 were also excluded from each list, however, some proteins with <20 
identified spectra were included if they were found to be associated with transcription, 
ubiquitin or the proteasome.    
 LC-MS/MS results of the erg6Δ untreated sample included a total of 35 proteins 
identified (Table 7). All 12 subunits of RNAPII were detected as well as an additional 7 
transcription associated proteins, including Rtr1, with 3 total spectra identified. In 
addition, 6 ubiquitin related proteins with a total of 22 spectra and 3 proteasome-
associated proteins, with a total of 7 spectra were revealed. A total of 32 proteins were 
identified in the MG132 treated erg6Δ sample and included in Table 8. Along with all 12 
subunits of RNAPII, an additional 5 transcription related proteins (Ctr9, Dst1, Spt5, Spt6, 
and Tfg1) were identified in the analysis. Furthermore, proteins associated with both 
ubiquitin (5 proteins) and the proteasome (2 proteins) were identified. The MuDPIT  
results for the untreated erg6Δ rtr1Δ sample are presented in Table 9. In all, 23 proteins 
were identified including 3 of the 12 RNAPII subunits (Rpb1, Rpb2, and Rpb9). The 
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remaining proteins listed in Table 9 did not meet the inclusion criteria of ≥ 20 spectra, but 
were included as a comparison to the MG132 treated erg6Δ rtr1Δ results (Table 10). The 
lack of RNAPII proteins pulled-down in the untreated erg6Δrtr1Δ sample is in agreement 
with purification results seen in Figures 14 and 15.   
 Spectra identified in the double mutant, erg6Δ rtr1Δ preparation included 80 
proteins with 12 of the 13 most abundant comprising subunits of RNAPII. Also present, 
were 4 proteasomal proteins (Rpn2, Rpn4, Rpn6, and Rpt3) as well as 9 ubiquitin 
associated proteins.  
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Table 7. Proteins identified using Scaffold analysis for untreated 
Rpb3-TAP erg6Δ 
Accession # Identified Proteins  Mol Wt Total Spectra 
gi|6320061 Rpb1; TXN  192 kDa 6892 
gi|6324725 Rpb2; TXN  139 kDa 5669 
gi|6322168 Rpb3; TXN  35 kDa 2090 
gi|6322321 Rpb4; TXN  25 kDa 1281 
gi|6319630 Rpb5; TXN  25 kDa 1014 
gi|6324569 Rpb11; TXN  14 kDa 703 
gi|6321368 Rpb9; TXN  14 kDa 484 
gi|6320612 Rpb7; TXN  19 kDa 483 
gi|6325445 Rpb6; TXN  18 kDa 465 
gi|6324798 Rpb8; TXN  17 kDa 458 
gi|6324784 Rpb10; TXN  8 kDa 383 
gi|6321937 Rpb12; TXN  8 kDa 323 
gi|6323196 Rps31p  17 kDa 63 
gi|6323462 Sen1p  253 kDa 34 
gi|6323522 Taf8p  58 kDa 26 
gi|6322881 Set3p  85 kDa 25 
gi|6323115 Smc4p  162 kDa 24 
gi|10383754 Mrc1p  124 kDa 21 
gi|6322409 Tdh1p  36 kDa 21 
gi|6321631  Tdh3p  36 kDa 21 
gi|37362706 Asr1; TXN  33 kDa 3 
gi|330443717 Ctr9; TXN  125 kDa 2 
gi|6323931 Bul1p  109 kDa 5 
gi|6323525 Bul2p  105 kDa 3 
gi|6321395 Dst1; TXN  35 kDa 11 
gi|6325360 Pre2p  32 kDa 3 
gi|6320859 Rpn3p  60 kDa 2 
gi|6325365 Rpn7p  49 kDa 2 
gi|6321193 Rtf1; TXN  66 kDa 2 
gi|6320987 Rtr1; TXN  26 kDa 3 
gi|6323632 Spt5; TXN  116 kDa 9 
gi|6321552 Spt6; TXN  168 kDa 12 
gi|6320598 Uba2p  71 kDa 3 
gi|6320999 Ubp3p  102 kDa 3 
gi|6320945 Ubp9p  86 kDa 5 
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Table 8. Proteins identified using Scaffold analysis for MG132 
treated Rpb3-TAP erg6Δ 
Accession # Identified Proteins Mol Wt Total Spectra 
gi|6320061 Rpb1; TXN           192 kDa   7568 
gi|6324725 Rpb2; TXN  139 kDa 5720 
gi|6322168 Rpb3; TXN  35 kDa 1486 
gi|6324569 Rpb11; TXN  14 kDa 1074 
gi|6319630 Rpb5; TXN  25 kDa 755 
gi|6322321 Rpb4; TXN  25 kDa 498 
gi|6321937 Rpb12; TXN  8 kDa 439 
gi|6324784 Rpb10; TXN  8 kDa 431 
gi|6324798 Rpb8; TXN  17 kDa 333 
gi|6321368 Rpb9; TXN  14 kDa 228 
gi|6325445 Rpb6; TXN  18 kDa 219 
gi|6320612 Rpb7; TXN  19 kDa 67 
gi|330443717 Ctr9; TXN  125 kDa 5 
gi|6321395 Dst1; TXN  35 kDa 6 
gi|6323632 Spt5; TXN  116 kDa 5 
gi|6321552 Spt6; TXN  168 kDa 4 
gi|6321625 Tfg1; TXN  82 kDa 2 
gi|6319612 Mec1p  273 kDa 41 
gi|6324376  YNR048W  45 kDa 32 
gi|6323457 Tus1p  149 kDa 32 
gi|6320887 Sap1p  100 kDa 30 
gi|6323548 Rpm2p  139 kDa 27 
gi|6324132 Whi3p  71 kDa 25 
gi|6319977 Whi4p  71 kDa 24 
gi|6320433 Sir4p  152 kDa 23 
gi|6323547 Pre8p  27 kDa 2 
gi|6320184 Rpn4p  60 kDa 5 
gi|330443700 Ubp10p  89 kDa 7 
gi|6320999 Ubp3p  102 kDa 4 
gi|6322035 Ubp7p  123 kDa 3 
gi|6321623 Ubr1p  225 kDa 3 
gi|6323712 Ubx4p  47 kDa 2 
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Table 9. Proteins identified using Scaffold analysis for untreated  
Rpb3-TAP erg6Δrtr1Δ 
Accession # Identified Proteins Mol Wt Total Spectra 
gi|6324725 Rpb2; TXN 139 kDa 314 
gi|6320061 Rpb1; TXN 192 kDa 221 
gi|6324472 Pkh2p 122 kDa 7 
gi|6321368 Rpb9; TXN 14 kDa 13 
gi|6320512 YDR306C 54 kDa 9 
gi|6323568 Tcb3p 171 kDa 2 
gi|6322179 Tir3p 26 kDa 2 
gi|6321891 Tra1p 433 kDa 5 
gi|6321012 Chd1p 168 kDa 2 
gi|6321289 Ino80p 171 kDa 2 
gi|6322163 Irr1p 133 kDa 2 
gi|6320345 Dop1p 195 kDa 2 
gi|6325121 Gip3p 141 kDa 2 
gi|6323403 Rom2p 153 kDa 2 
gi|6322125 See1p 29 kDa 5 
gi|6319318 Nup60p 59 kDa 2 
gi|6320792 YEL043W 106 kDa 3 
gi|330443395 Pkc1p 131 kDa 2 
gi|6323587 Cyb2p 66 kDa 2 
gi|157285914 YKR005C 59 kDa 2 
gi|6319528 Yro2p 39 kDa 2 
gi|6322047 Tid3p 80 kDa 2 
gi|6322266 Cdc6p 58 kDa 2 
 
Although there were no specific interactions found in the purified samples with 
ubiquitin, there were several proteins identified that associate with ubiquitin. In addition, 
several subunits of the proteasome were identified in all samples albeit in low abundance 
(see Tables 7-10). Notably, although there is an increase in the total number of protein 
identified, there is a lack of elongation factors associated with the double deletion mutant, 
erg6Δrtr1Δ treated with MG132. Conversely, the number of ubiquitin proteins was the 
highest, although at low spectral levels, found to associate with RNAPII (Table 10).    
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Table 10. Proteins identified using Scaffold analysis for MG132 treated 
Rpb3-TAP erg6Δrtr1Δ 
Accession # Identified Proteins  Mol Wt Total Spectra 
gi|6320061 Rpb1; TXN 192 kDa 11465 
gi|6324725 Rpb2; TXN 139 kDa 9265 
gi|6322168 Rpb3; TXN 35 kDa 2133 
gi|6324569 Rpb11; TXN 14 kDa 1617 
gi|6319630 Rpb5; TXN 25 kDa 1056 
gi|6322321 Rpb4; TXN 25 kDa 894 
gi|6321937 Rpb12; TXN 8 kDa 721 
gi|6321368 Rpb9; TXN 14 kDa 708 
gi|6324798 Rpb8; TXN 17 kDa 673 
gi|6324784 Rpb10; TXN 8 kDa 441 
gi|6325445 Rpb6; TXN 18 kDa 403 
gi|6323854 Cik1p 69 kDa 155 
gi|6320612 Rpb7; TXN 19 kDa 144 
gi|6319982 Dtd1p 17 kDa 72 
gi|6321631  Tdh3p 36 kDa 54 
gi|6322409 Tdh1p 36 kDa 50 
gi|6319612 Mec1p 273 kDa 46 
gi|6324917 Rpa190p 186 kDa 46 
gi|6320913 Arg5,6p 95 kDa 45 
gi|6323457 Tus1p 149 kDa 44 
gi|6324472 Pkh2p 122 kDa 39 
gi|6319295 Lte1p 163 kDa 36 
gi|6321978 Ssp1p 66 kDa 36 
gi|6320887 Sap1p 100 kDa 35 
gi|6324553 Tat2p 65 kDa 34 
gi|6323548 Rpm2p 139 kDa 33 
gi|6325167 Rps6ap 27 kDa 31 
gi|6319975 Gcs1p 39 kDa 30 
gi|6320433 Sir4p 152 kDa 29 
gi|7276233 Yck3p 60 kDa 29 
gi|6319279 Cdc19p 55 kDa 28 
gi|6319986 Gdh2p 124 kDa 28 
gi|6324452 Rpl18ap 21 kDa 28 
gi|6325121 Gip3p 141 kDa 27 
gi|6325016 Hsp82p 81 kDa 27 
gi|10383781 Pgk1p 45 kDa 27 
gi|6324445 Rpl25p 16 kDa 27 
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Table 10 (continued). Proteins identified using Scaffold analysis for 
MG132 treated Rpb3-TAP erg6Δrtr1Δ 
Accession # Identified Proteins  Mol Wt Total Spectra 
gi|6319977 Whi4p 71 kDa 27 
gi|6324132 Whi3p 71 kDa 26 
gi|6322079 Hos4p 124 kDa 25 
gi|6322668 Rpl17ap 21 kDa 25 
gi|154200011 Rpl20bp 20 kDa 25 
gi|144228166 Ssa1p 70 kDa 25 
gi|6323196 Rps31p 17 kDa 24 
gi|6325252 Aep3p 70 kDa 23 
gi|6321968 Eno2p 47 kDa 23 
gi|6323585 Imd4p 56 kDa 22 
gi|6325300 Rpl43ap 10 kDa 22 
gi|6321754 Rpl8ap 28 kDa 22 
gi|6323844 Sgs1p 164 kDa 22 
gi|6321921 Arp1p 43 kDa 21 
gi|6324870  YOR296W 147 kDa 21 
gi|6321948 Rtt107p 123 kDa 21 
gi|10383795 Snt1p 138 kDa 21 
gi|6319396 Ssa3p 71 kDa 21 
gi|6321012 Chd1p 168 kDa 20 
gi|6321243 Gcn1p 297 kDa 20 
gi|330443652 Hsl1p 170 kDa 20 
gi|6323135 Mdn1p 559 kDa 20 
gi|6321812 Myo1p 224 kDa 20 
gi|14318555 Rpl2ap 27 kDa 20 
gi|6322000 Skn7p 69 kDa 20 
gi|6320795 Utr2p 50 kDa 20 
gi|6321709 Yta7p 157 kDa 20 
gi|6323632 Spt5; TXN 116 kDa 16 
gi|6322115 Rpn2p 104 kDa 3 
gi|6320184 Rpn4p 60 kDa 7 
gi|6320106 Rpn6p 50 kDa 14 
gi|6320602 Rpt3p 48 kDa 3 
gi|6321193 Rtf1; TXN 66 kDa 4 
gi|330443605 Set2; TXN 84 kDa 9 
gi|6322264 Ubp12p 143 kDa 5 
gi|330443411 Ubp13p 84 kDa 6 
gi|6325184 Ubp16p 57 kDa 5 
gi|6320999 Ubp3p 102 kDa 6 
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Table 10 (continued). Proteins identified using Scaffold analysis for 
MG132 treated Rpb3-TAP erg6Δrtr1Δ 
Accession # Identified Proteins  Mol Wt Total Spectra 
gi|14318532 Ubp6p 57 kDa 5 
gi|6322035 Ubp7p 123 kDa 6 
gi|6323879 Ubp8p 54 kDa 3 
gi|6321623 Ubr1p 225 kDa 5 
gi|6323052 Ubr2p 217 kDa 8 
  
PTM analysis for ubiquitin addition (ie. Gly-Gly or mass shift of +114 in 
MS/MS) revealed there were potential ubiquitination sites in the erg6Δ rtr1Δ in the 
presence of MG132 identified in Rpb2 and Rpb6. Figure 16 shows the Rpb2 sequence 
coverage obtained in MS/MS analysis. The sequence of the potential ubiquination 
modification site was located in the amino acid sequence: K.RIQYAKDILQK(+114).E. 
However, it is unlikely that this peptide would truly be a site of ubiquitin modification 
due several issues. The peptide is short with only 11 residues and only a [M +2] charge 
state. In addition, there were only 2 spectra counted, and a greater number of counts 
would be expected if it were truly a site of modification. Furthermore, although a 
modified lysine residue was identified, it was not covered in the CID spectrum. 
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 The representative sequence coverage for Rpb6 obtained from the erg6Δrtr1Δ in 
the presence of MG132 seen in Figure 17 displays a sequence containing a potential 
ubiquination site which is more likely than that indicated in the Rpb2 subunit when 
considering the analysis of the ion fragmentation spectra in addition to the high sequence 
coverage. The sequence, K.DGETTDANGK*IVTGGNGPEDFQQHEQIR.R, where K* 
is the potential modification site for ubiquitin addition with mass shift +114, contains 33 
amino acids and has one missed cleavage at an interior lysine residue. Further confidence 
in this potential modification site is seen from the spectra (Figure 17). Notably, the 
precursor ion has a low parent mass error score and a +3 charge state which strengthens 
Figure 16. Peptide sequence coverage of RNAPIIs second largest subunit Rpb2 obtained from 
erg6Δrtr1Δ in the presence of MG132 using Scaffold software. Yellow highlighted areas indicate 
peptide sequences identified by LC-MS analysis; Green highlighted amino acids are residues of 
possible modification; Red outlined sequence indicates potential ubiquitination site. The identified 
spectra containing residues 348-358 with sequence: K.RIQYAKDILQK(+114).E modified at K358. 
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confidence in the identification of this modified peptide as there are potentially more 
spectra identified with higher charge states.  
 
V. Identification of phosphorylation sites in RNA Polymerase II purifications 
using a two-step bioinformatics analysis 
Since Rtr1 is a protein phosphatase, we also performed a search for changes in the 
phosphorylation status of RNAPII in the MG132 erg6Δ rtr1Δ samples relative to paired 
controls. One potential site was identified in Rpb1 just before the CTD in the linker 
region at threonine 1471. The total sequence coverage of Rpb1 provided in Figure 18 
Rpb6 Peptide: K.DGETTDANGK(+114)TIVTGGNGPEDFQQHEQIR.R 
2 Spectra; ID’d by X!Tandem only 
PUTATIVELY IDENTIFIED 
Figure 17. Peptide sequence coverage and ion fragmentation spectra of RNAPIIs subunit Rpb6 obtained 
from erg6Δrtr1Δ in the presence of MG132 using Scaffold software. Yellow highlighted areas indicate 
peptide sequences identified by LC-MS analysis; Green highlighted amino acids are residues of possible 
modification; Red outlined sequence indicates potential ubiquitination site. The identified spectra 
containing residues 37-65 with sequence: K.DGETTDANGK(114+)IVTGGNGPEDFQQHEQIR.R 
modified at K46. 
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indicates the peptide sequence for the potential modification site outlined in red. 
 
The peptide containing the potential site has 29 amino acids with sequence: 
ITEIEDGQDGGVT(+80)PYSNESGLVNADLDVK and was observed 33 times in the 
LC-MS run with an additional 12 unmodified spectra of the same peptide. The 
fragmentation spectra (Figure 19A and B) shows a +3 precursor ion charge state, low 
parent error for both spectra and no or limited neutral loss in the modified and 
unmodified spectra (Figure 19B). 
 
 
Figure 18. Sequence coverage of Rpb1 obtained following erg6Δ rtr1Δin the presence of MG132 
using Scaffold software. Yellow highlighted areas indicate peptide sequences identified by LC-MS 
analysis; Green highlighted amino acids are residues of possible modification; Red outlined sequence 
indicates potential phosphorylation site. The identified spectra containing residues 1459-1487 with 
sequence: K.DGETTDANGK(114+)IVTGGNGPEDFQQHEQIR.R modified at T1471.  
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VI. Can Threonine 1471 be dephophosphorylated by Rtr1 in vitro? 
In order to determine if the phosphorylated peptide sequence is a substrate of the 
phosphatase Rtr1, synthetic peptides of both modified and unmodified linker region were 
generated and used in an in vitro phosphatase assay. The assay was performed using a 
Malachite Green Phosphate Assay using a recombinant GST-Rtr1 added to mixtures 
containing either modified and unmodified peptides. Figure 20 shows the activity graph 
for multiple concentrations of Rtr1. The unmodified peptide showed a higher absorbance 
measurement at 620nm than the phosphorylated peptide indicating that more phosphate 
B
.
A
.
Figure 19. Ion fragmentation spectra obtained from LC-MS/MS for erg6Δ rtr1Δin the presence 
of MG132 using Scaffold software. A. Unmodified spectra of peptide containing Rpb1 residues 
1459-1487 (ITEIEDGQDGGVTPYSNESGLVNADLDVK). B. Spectra of peptide containing 
Rpb1 residues 1459-1487 (ITEIEDGQDGGVT(+80)PYSNESGLVNADLDVK) with identified 
phosphorylation site at threonine 1471 (T+80)  
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was released in the unmodified reaction wells which is likely background level 
phosphatase release; therefore, we cannot conclude that the peptide is a substrate of Rtr1 
at this time but this part of the project will be continued by other members of the 
laboratory.  
 
 
  
Rtr1 phosphatase activity on synthetic CTD Linker peptide
Figure 20. Malachite Green Phosphate Assay using recombinant GST-Rtr1 for potential substrate. 
Phosphorylated (Blue) and unmodified (Red) synthetic CTD peptides were incubated with various 
concentrations of Rtr1 and a phosphatase activity curve for each peptide was generated. Data does not 
conclusively identify the synthetic peptide as a substrate for Rtr1.  
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DISCUSSION  
Through the use of RTR1 deletion strains, proteomic LC-MS/MS analysis and 
ChIP experiments, the regulatory role of Rtr1 in dephosphorylation of S5-P during 
transcription elongation was established (Mosley et al., 2009). In addition to the 
accumulation of S5-P in the transcribed region in rtr1Δ, in an in vitro phosphatase assay 
Rtr1 dephosphorylated RNAPII phosphorylated at S5 residues. Additional studies since 
have identified an increase in interaction between RNAPII CTD and the proteasome, the 
cellular protein degradation machinery, in the absence of Rtr1 (see Table 2) which 
prompted this current investigation into what role Rtr1 plays in the degradation or 
turnover of the RNAPII during active transcription. Specifically, there were three aims 
for these studies: 1) Determine if CTD hyperphosphorylation due to loss of the CTD 
phosphatase, Rtr1, promotes RNAPII turnover and degradation; 2) Determine if CTD 
hyperphosphorylation due to the loss of the CTD phosphatase, Rtr1, promotes increased 
interaction with ubiquitin-proteasome associated proteins; and 3) Identify novel post-
translational modifications in the RNAPII complex following proteasome inhibition 
using MuDPIT analysis. To that end, mutant strains of S. cerevisiae were subjected to 
proteasomal inhibition, affinity purification and subsequent proteomic analysis via mass 
spectrometry to identify any post-translational modifications and potential proteasomal 
interactions with the RNAPII complex.  
The modification state of RNAPII and especially the CTD of its largest subunit, 
Rpb1, is critical to transcription and gene expression (for recent review see Hsin & 
Manley, 2012).  The results reported from immunoblot analysis (Figure 7 and 9) in this 
work confirm previous findings of accumulation of S5-P CTD in rtr1Δ mutants (Mosley 
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et al., 2013; Mosley et al., 2009). The importance of this hyperphosphorylation has 
consequences for transcription in several key ways, as it has been shown to be involved 
in the recognition or recruitment of elongation factors, chromatin remodeling, histone 
methylation, capping enzymes, and termination factors (Fabrega et al., 2003; Hampsey & 
Reinberg, 2003; Phatnani & Greenleaf, 2006; Vasiljeva, Kim, Mutschler, Buratowski, & 
Meinhart, 2008). The increased accumulation of S5-P in the RTR1 deletion strains 
following treatment with the proteasome inhibitor, MG132 (Figure 7 and 9), supports our 
hypothesis that hyperphosphorylation does in fact promote targeting of RNAPII for 
degradation. The exact mechanism by which this occurs is not clear from this data, 
however, the potential link of this modification leading to increased interactions with the 
ubiquitin and proteasome related proteins are discussed in more detail below.  
In contrast to the accumulation of hyperphosphorylated RNAPII, the decreased 
recovery of RNAPII in the untreated Rpb3-TAP erg6Δ rtr1Δ in comparison to the 
MG132 treated Rpb3-TAP erg6Δ rtr1Δ cells  was also noted (See Figures 14 and 15 in 
Results Section). Since the untreated cells were not subjected to proteasomal inhibition 
by MG132, this result has also been attributed to proteasome-dependent degradation of 
the RNAPII.  Alternatively, it is possible that the ubiquitination of the Rpb3 subunit alone 
could cause the reduction of overall RNAPII seen in Figures 14 and 15 since all 
purifications were performed using Rpb3-TAP as the bait. Performing this study with 
multiple TAP tagged endogenous subunit of RNAPII in replicate studies would possibly 
confirm that the overall reduction of RNAPII is due to proteasomal degradation and 
independent of the tagged subunit.  
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In addition to S5-P accumulation, S7-P was also more abundant in the absence of 
Rtr1 when compared to the ERG6 deletion background control pair as indicated in Figure 
9. This result is interesting as Rtr1 has not been shown to directly interact with S7-P, so 
levels throughout the transcribed region of the genes remain steady during transcription, 
or may even increase slightly toward the end of the reading frame, as previously noted 
(Chapman et al., 2007; M. Kim et al., 2009); we therefore would not expect to see a 
dramatic increase in this CTD mark with the loss of Rtr1. However, Egloff and 
colleagues have reported intriguing results that the S7-P signal is recognized by the 
human homolog of Rtr1, RNA Polymerase II-associated protein 2 (RPAP2). In fact, they 
used RPAP2 knockdown in mammalian cells to determine that not only is S7-P on the 
CTD necessary for interaction with RPAP2, but the mark is involved with RPAP2 
recruitment to actively transcribed snRNA genes (Egloff, Zaborowska, et al., 2012). 
These results highlight the importance of further investigation into what additional roles 
S7-P may play in gene expression.   
In addition to the increase in S7-P observed between erg6Δ and erg6Δ rtr1Δ, it 
appears that there is a small increase in S7-P when comparing the untreated to the 
MG132 treated pairs (Figures 8 and 9). This result may be attributed to the accumulation 
of transcriptionally active RNAPII that could not be degraded due to the proteasomal 
inhibition supporting the hypothesis that hyperphosphorylated CTD is more readily 
targeted for degradation by the proteasome.  
In contrast to the increases seen in the S5-P and S7-P modifications, Y1-P and S2-
P were not detected in any of the samples by western blot analysis likely due to 
insufficient levels of these modifications and/or low titer antibodies used for western blot 
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analysis (Figure 8). The anti-phosphorylated tyrosine antibody used for this study has 
since been shown to detect Y1-P using purified RNAPII samples instead of whole cell 
extracts (data not shown) and therefore likely has a low affinity for the modification. 
Phosphorylation at these CTD sites peaks toward the 3’end of the transcribed region 
(Mayer et al., 2012; Mayer et al., 2010) and have not been implicated in rtr1Δ defects. 
The lack of phosphorylation at these CTD residues suggests that the RNAPII could have 
been arrested early in transcriptional activities, possibly before the Y1-P and S2-P could 
be placed on the CTD, which is consistent with previous results reported by multiple 
groups (Heidemann & Eick, 2012; Mayer et al., 2012). Importantly, an apparent decrease 
was seen in overall RNAPII in the MG132 treated and untreated rtr1Δ double mutants 
when compared to the erg6Δ background (Figure 15). Our results show that inhibition of 
proteasomal activity resulted in an increased accumulation of proteins in treated erg6Δ 
rtr1Δ cells in comparison with its untreated counterpart (Figure 7 and 9 and 15). 
Moreover, when comparing the untreated cells with those exposed to MG132, there is a 
pronounced increase in the amount of purified RNAPII present in the MG132 treated 
double mutant cells (Figure 15). These results may indicate that MG132 inhibition 
decreased the turnover rate of RNAPII in the treated sample, whereas the lower yield of 
RNAPII seen in the untreated sample could be attributed to normally functioning 
proteasomal degradation in combination with the defects associated with rtr1Δ (Mosley 
et al., 2009). Notably, the effect is not present in the erg6Δ MG132 treated and untreated 
samples in Figure 15; a result which further increases our confidence in the hypothesis 
that the loss of Rtr1 is indeed a factor in increased targeting following proteasomal 
inhibition.  
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As mentioned previously in the Introduction, there are many recent studies 
focused on the role of the proteasome and transcriptional regulation as highlighted by 
recent reviews (Finley, Ulrich, Sommer, & Kaiser, 2012; Wilson et al., 2013). 
Ubiquitination is the means by which target proteins are marked for degradation by the 
proteasome through the addition of polyubiquitin chains reviewed in (Pickart & Eddins, 
2004). To evaluate the link of proteasomal degradation to RNAPII, proteomic analysis 
was carried out on all experimental samples. Affinity purification products of the rtr1Δ 
mutants and erg6Δ background strains were subjected to a database search in Scaffold 
software for proteins associated with transcription (TXN) and degradation as well as 
post-translational modifications for ubiquitin and phosphorylation. Protein identifications 
will be examined here while results of the post-translational modifications will be 
discussed below.  
The protein identifications obtained following LC-MS/MS analysis for each 
genotype are presented in Tables 7-10. The MG132 treated and untreated erg6Δ 
background strains had comparable overall total protein identifications with 35 proteins 
identified in the untreated and 32 proteins identified in the MG132 treated samples within 
our cutoffs, however, the content of the proteins identified interesting protein interactions 
(Tables 7 and 9) which appear to be active at different stages of transcription. For 
example, data presented in Table 7 shows that the untreated erg6Δ cells had the most 
transcription elongation-associated proteins detected of all 4 samples (Ctr9, Dst1, Rtf1, 
Spt5, Spt6, Asr1, Set3, and Rtr1), but only had one each of proteins associated with 
transcription initiation (Taf8) and transcription termination (Sen1). There were nine total 
ubiquitin and proteasomal proteins detected in the MS analysis in this data set. In 
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contrast, the MG132 treated erg6Δ sample recovered only 4 elongation related proteins 
(Ctr9, Dst1, Spt5, Spt6, see also Table 8), all of which we detected in the untreated 
sample as well. One transcription initiation protein was detected, Tfg1, which is the 
largest subunit of the TFIIF complex (Saccharomyces genome database at 
www.yeastgenome.org). There is, however a comparable number of ubiquitin and 
proteasome-associated proteins identified (Tables 7 and 8) between the untreated and 
treated erg6Δ samples. These results make it difficult to draw any conclusions regarding 
proteasome degradation since there is not a significant difference between the untreated 
and MG132 treated conditions. Of note, however, is the lack of elongation factors 
associated with MG132 treatment. It is possible that the proteasome inhibition caused a 
reduction of total RNAPII occupancy during elongation, resulting in abrupt dissociation 
and subsequent reduction in association of the RNAPII with elongation factors. This 
could be investigated through the use of ChIP following MG132 treatment.     
There is a large difference between the total number of proteins identified 
between the treated and untreated rtr1Δ double mutants. As indicated in Tables 9 and 10, 
there were no proteins associated with the proteasome or ubiquitin in the untreated erg6Δ 
rtr1Δ while the MG132 treated erg6Δ rtr1Δ yielded the most proteins and total spectra of 
the four conditions assessed. The total RNAPII for the untreated erg6Δ rtr1Δ was very 
low (Figures 14 and 15) and this result partially accounts for the overall poor yield of 
MS/MS data. Poor purification and sample preparation prior to MS analysis could also 
contribute to poor MS/MS evaluation. The treated erg6Δ rtr1Δ sample revealed the most 
interactions of the 4 assessed conditions with proteins associated with the proteasome 
(Rpn2, Rpn4, Rpn6, and Rpt3) and ubiquitin related proteins (Ubp12, Ubp13, Ubp16, 
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Ubp3, Ubp6, Ubp7, Ubp8, Ubr1, and Upr2).The increase in interactions with the 
proteasome and ubiquitin associated proteins in the MG132 treated er6gΔ rtr1Δ cells 
supports our hypothesis that there is increased interaction of the proteasome with 
hyperphosphorylated RNAPII.  
Presented in Table 11 is a summary comparison of the transcription-related, 
ubiquitin-related and proteasomal-related proteins detected in the MS/MS results. As 
noted for the MG132 treated background erg6Δ results, there is a distinct lack of 
elongation factors detected in the MG132 treated erg6Δ rtr1Δ cells. Of the four that were 
identified (Chd1, Spt5, Rtf1, and Set2) only one was common to the MG132 treated 
erg6Δ (Tables 10 and 11). This suggests that the cellular pool of RNAPII was different 
than that purified from erg6Δ, presumably due to the hyperphosphorylation of the CTD, 
but it is possible the decrease in RNAPII association with elongation factors due to 
incompetent RNAPII or RNAPII which is not locally available for transcription.  An 
analogous situation has been recently published by Forget and coworkers regarding 
RPAP2, the human homolog of Rtr1 (Forget et al., 2013). Results of localization studies 
indicate that the human CTD phosphatase is a bifunctional regulatory enzyme which not 
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only dephosphorylates the CTD in the nucleus, but also regulates the availability of 
assembled RNAPII complex by co-transporting with it from the cytoplasm into the 
nucleus (Forget et al., 2013). When RPAP2 was knocked down using siRNA, RNAPII 
was sequestered in the cytoplasm (Forget et al., 2013). Considering Forget and coworkers 
found that RNAPII is transported into the nucleus in a fully assembled complex and our 
findings of the MG132 treatment of erg6Δ rtr1Δ, the depleted levels of interaction with 
elongation factors may be due to RNAPII being exported to the cytoplasm and 
unavailable for transcription. Additional studies to investigate the localization of RNAPII 
in MG132 treated rtr1Δ will need to be performed to investigate the validity of this 
mechanism and to determine if the RNAPII is transported out of the nucleus to be 
targeted for proteasomal degradation.     
The most common and best studied PTMs are reversible phosphorylation and 
ubiquitination for which MS is a uniquely powerful tool suited to their characterization 
through the peptide fragmentation patterns achieved following collision induced 
Table 11. Summary Comparison of detected proteins from MS/MS data 
  erg6Δ erg6Δrtr1Δ 
  Untreated MG132 Treated Untreated MG132 Treated 
Transcription 
Phase 
Initiation Taf8 Tfg1 N/A N/A 
Elongation 
Ctr9, Dst1, 
Rtf1, Spt5, 
Spt6, Asr1, 
Set3, Rtr1 
Ctr9, Dst1, 
Spt5, Spt6 
Tra1, Chd1 Chd1, Spt5, 
Rtf1, Set2 
Termination Sen1 N/A N/A N/A 
Ubiquitin related 
Bur1, Bur2, 
Uba2, Uba3, 
Uba9 
Ubp10, Ubp3, 
Ubp7, Ubr1, 
Ubx4 
N/A Ubp12, Ubp13, 
Ubp16, Ubp3, 
Ubp6, Ubp7, 
Ubp8, Ubr1, 
Upr2 
Proteasome related 
Pre2, Rpn3, 
Rpn7 
Pre8, Rpn4 N/A Rpn2, Rpn4, 
Rpn6, Rpt3, 
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dissociation. As a goal of these current studies, determination of post translational 
modifications was important due to a variety of systemic biological functions attributed 
to the dynamic interactions of these alterations. The first, and most important step in 
studying PTMs is to determine the type and site of modification (Salzano & Crescenzi, 
2005). Consequently, spectra obtained from erg6Δ background and erg6Δrtr1Δ mutant 
samples were subjected to a database search using SEQUEST followed by Scaffold 
analysis. Database searches of obtained MS spectra were conducted for ubiquitination 
modifications for all experimental conditions. The resulting identification of potential 
ubiquitination sites not previously reported were found only in the MG132 treated erg6Δ 
rtr1Δ. The sites were located in Rpb2 and Rpb6 at locations K358 and K46, respectively 
(Figures 16 and 17). The confidence in PTM identification is stronger for the Rpb6 
modification than that the site of modification identified for Rpb2 based on the collected 
MS/MS data. This site could be confirmed through the use of an in vitro ubiquitination 
assay and MS analysis to assess whether the synthetic peptide matches the experimentally 
derived sequence as reported previously (Somesh et al., 2005).  
An important point to review here is that only two ubiquitin modification sites 
related to RNAPII have been reported for Rpb1 using both in vivo and in vitro methods to 
elucidate the sites (Peng et al., 2003; Somesh et al., 2005; Somesh et al., 2007), despite 
evidence of ubiquitin dependent regulation of RNAPII being well documented (Collins & 
Tansey, 2006; and recently reviewed in Hammond-Martel, Yu, & Affar el, 2012). The 
lack of ubiquitin site identification can be credited to the discovery that MS sample 
preparations using iodoacetamide as an alkylating agent caused spectral artifacts that 
mimicked ubiquitin modifications in MS/MS analysis. The presence of diglycine 
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modifications on lysines contributed greatly to the high false discovery rates of ubiquitin 
modifications (Nielsen et al., 2008). As a consequence, the use of chloroacetamide as an 
alkylating reagent to modify digested samples was recommended.  In our study, several 
factors are thought to have contributed to the low incidence of ubiquitin modification 
identified. One potential source of low yield is the potential deubiquitinase activity. 
Despite the use of chloroacetamide in peptide digest preparations, which alkylated 
the cysteine(s) in ubiquitin proteases, additional measures should have been taken to 
inhibit deubiquitinase enzymes during cell lysis to control for ubiquitin degradation 
during and after purification processing. This would ensure that ubiquitin was not 
removed by specific proteases and improve the likelihood of ubiquitin modification 
identification in MuDPIT analysis. In fact, in our data we saw specific association of a 
number of ubiquitin proteases in the erg6Δ rtr1Δ MG132 treated sample (specifically: 
Ubp12, Ubp13, Ubp16, Ubp3, Ubp6, Ubp7, Ubp8).  In addition to the addition of an 
ubiquitin protease inhibitor during cell lysis, incorporation of an enrichment step into the 
purification process or even during pre-analytical sample preparations would potentially 
increase the relative abundance of the modified peptides. In fact, planned follow up 
studies include the addition of a ubiquitin tag similar to the TAP tag using homologous 
recombination techniques previously described (See Introduction and Methods). The 
proposed enrichment involves a two-step affinity purification through 
immunoprecipitation for RNAPII followed by ubiquitin. The studies will ideally reveal 
proteome changes associated with ubiquitin.    
In the case of phosphorylation a positive mass shift of 80 Da associated with a 
tyrosine, serine, or threonine residue is seen on the modified spectra. Upon fragmentation 
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of many of these peptide ions with collision induced dissociation a neutral loss of -98 
daltons is often observed. The MS/MS PTM search results obtained for erg6Δrtr1Δ 
revealed a potential phosphorylation site in the linker region between the globular domain 
and the CTD of the largest RNAPII subunit, Rpb1 (Figures 17 and 18). This T1471 
phosphorylation site has not been previously detected in our lab despite exhaustive PTM 
searches on wild-type S. cerevisiae strains. Interestingly, phosphorylation at this site has 
been independently reported following a phosphorylation analysis using tandem MS in 
two separate studies although a biological role for this modification is not known 
(Albuquerque et al., 2008; Mohammed et al., 2008). In the first study, Albuquerque and 
colleagues performed a global phoshoproteome analysis using various separation 
strategies to enrich for and then identify low abundance phosphopeptides which yielded 
an increased amount of phosphorylation. In the second experiment, Mohammed and 
coworkers were able to achieve almost 100% sequence coverage of the subunits of 
RNAPII and RNAPIII using multiple proteases (including trypsin, chymotrypsin, and 
GluC) to digest samples which enriched for phosphoproteins and then subjected them to 
LC-MS/MS with sequential electron transfer dissociation (ETD) and CID in order to 
obtain the highest sequence coverage possible. In the process multiple phospho-protein 
identifications were achieved. Interestingly, the T1471 phosphopeptide was reported by 
Mohammed et al. although the authors used a high 5% FDR. To our knowledge, no 
further studies have been reported elucidating the importance of this particular PTM.  
Future studies in the Mosley laboratory could focus on performed in vivo analysis of the 
role of T1471 phosphorylation in the regulation of RNAPII transcription.  Additionally, 
this dataset indicates that Rtr1 might be involved in the regulation of T1471 levels in 
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vivo.  Although our initial attempts at in vitro T1471 dephosphorylation failed (Figure 
20), future studies could use a more sensitive approach to measure changes in T1471 
levels in the presence or absence of Rtr1 such as ELISA and/or multiple reaction 
monitoring (MRM) experiments.          
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CONCLUSION 
 The role that the CTD phosphatase Rtr1 has in the regulation of transcription has 
been discovered; however, it is still incompletely understood. Preliminary data collected 
by Mosley and colleagues (Table 2) documented an increased association of RNAPII 
with members of the ubiquitin-proteasome system in Rtr1 deletion strains of S. 
cerevisiae. As a consequence, the studies presented here aimed to further characterize the 
role of Rtr1 in RNAPII recycling through the use of proteomic analysis to reveal potential 
protein interactions with the members of the ubiquitin-proteasome system and potential 
sites of post-translational modification with in the RNAPII complex that may be involved 
in regulation of transcription. 
 The original hypothesis that the hyperphosphorylation of the CTD due to a loss of 
Rtr1 phosphatase activity increased RNAPII complex turnover was supported by the 
accumulation of S5-P CTD (Figure 7 and 9) following RNAPII purification in the 
presence of the proteasome inhibitor, MG132. Additionally, hyperphosphorylation was 
linked to increasing interaction of RNAPII the proteasome through MuDPIT data 
revealing an increased number of ubiquitin related and proteasomal proteins associated 
with RNAPII in MG132 treated extracts (Tables 7-10).  
The final aim of these studies revealed potential ubiquitin and phosphorylation 
PTMs in the RNAPII subunits.  Rpb2 and Rpb6 had ubiquitin sites identified (Figures 16 
and 17), however, there is a low likelihood that the Rpb2 site can be confirmed due to 
low spectrum quality. The confirmation of the phosphorylation site found on Rpb1, 
T1471 (Figure 18 and 19), is continuing in our laboratory through  the use of a synthetic 
phosphopeptide matching the sequence obtained from MS data as well as its unmodified 
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form. Several in vitro follow up functional analyses are planned to evaluate the synthetic 
phosphopeptide with the goal to gain insight into the importance of this modification to 
transcriptional control. These studies will include additional phosphate assays to 
investigate whether this site is a substrate of Rtr1 and MS/MS analysis following 
digestion of the synthetic peptide.  Additionally, we propose production of T1471-site 
specific antibody to be used in assays such as ELISA, Western blot analysis, and ChIP. 
Finally, the use of site specific mutagenesis could help to determine the biological 
significance of phosphorylation event and how loss of this modification affects RNAPII 
function.  
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Promotion History: Product Support Scientist (Oct 2002-Jan 2003); Research Scientist 
(Jan 2003-Sept 2006) 
 
Infectious Disease Division, Indiana University School of Medicine, Indianapolis, IN 
Key Responsibilities:  
 Managed biospecimen processing laboratory supporting HIV clinical trials 
including preparation of samples for College of American Pathologist’s 
accreditation (CAP) for HIV-1 Viral Load (RT-PCR) and CD4/CD8 
Determinations (Flow Cytometry) 
 Drafted and updated clinical and research protocols ACTG trials and collaborative 
research studies using flow cytometry in areas such as Apoptosis, isolation of 
lymphocytic and dendritic cells using FACS (4-color), intracellular cytokine 
markers, and cell cycle analysis using propidium iodide.  
 
 
Promotion History: Research Technician, RS07 (Jun 2000-Jul 2001); Research Analyst, 
PA (Aug 2001-Oct 2002) 
 
Mid America Clinical Laboratories, Indianapolis, IN  
Key Responsibilities: 
 Maintained QC/QA logs and produced troubleshooting procedure guide for SOPs 
 Developed strong attention to detail, troubleshooting and creative problem solving 
skills while assisting in surgical tissue examinations through set-up, accessioning 
and preparation of 1/3 of overall case load (approx. 80,000 surgicals/yr) 
 Maintained instrumentation including cryo-microtome, balances, tissue 
processors, automated tissue staining and cover-slipping instruments 
Promotion History: Laboratory Assistant, Histology (Sept 1997-Sept 1998); Laboratory 
Assistant, Pathology (Oct 1998-Jun 2000) 
 
PA Labs, Inc., Muncie, IN  
 
Key Responsibilities: 
 Performed testing and reported results for Hematology, Chemistry, Microbiology, 
Urinalysis, Immunology, and Special Chemistry 
 Reviewed QC/QA logs and report any out of specification results to supervisor 
 Prepared standards and reagents for calibration and general instrument maintenance 
Promotion History: Special Qualified Medical Technologist (1996-1997) 
 
 
